Compositions and methods for modulating vascular development

ABSTRACT

The present invention provides methods of using EGFL7 antagonist to modulate vascular development. Also provided herein are methods of screening for modulators of EGFL7 activity. Furthermore, methods of treatment using EGFL7 antagonists are provided.

RELATED APPLICATIONS

This application is a continuation of International Application No.PCT/US2005/013658, filed Apr. 14, 2005, which claims the benefit of U.S.Provisional Application No. 60/562,054, filed Apr. 14, 2004.

FIELD OF THE INVENTION

The present invention relates generally to compositions and methods thatare useful for modulating vascular development. Specifically, thepresent invention relates to EGF-like domain 7 (EGFL7), a novelendothelial cell-derived secreted factor. The present invention furtherrelates to the diagnosis and treatment of conditions and diseasesassociated with angiogenesis.

BACKGROUND OF THE INVENTION

Development of a vascular supply is a fundamental requirement for manyphysiological and pathological processes. Actively growing tissues suchas embryos and tumors require adequate blood supply. They satisfy thisneed by producing pro-angiogenic factors, which promote new blood vesselformation via a process called angiogenesis. Vascular tube formation isa complex but orderly biological event involving all or many of thefollowing steps: a) Endothelial cells (ECs) proliferate from existingECs or differentiate from progenitor cells; b) ECs migrate and coalesceto form cord-like structures; c) vascular cords then undergotubulogenesis to form vessels with a central lumen d) existing cords orvessels send out sprouts to form secondary vessels; e) primitivevascular plexus undergo further remodeling and reshaping; and f)peri-endothelial cells are recruited to encase the endothelial tubes,providing maintenance and modulatory functions to the vessels; suchcells including pericytes for small capillaries, smooth muscle cells forlarger vessels, and myocardial cells in the heart. Hanahan, D. Science277:48-50 (1997); Hogan, B. L. & Kolodziej, P. A. Nature ReviewsGenetics. 3:513-23 (2002); Lubarsky, B. & Krasnow, M. A. Cell. 112:19-28(2003).

It is now well established that angiogenesis is implicated in thepathogenesis of a variety of disorders. These include solid tumors andmetastasis, atherosclerosis, retrolental fibroplasia, hemangiomas,chronic inflammation, intraocular neovascular diseases such asproliferative retinopathies, e.g., diabetic retinopathy, age-relatedmacular degeneration (AMD), neovascular glaucoma, immune rejection oftransplanted corneal tissue and other tissues, rheumatoid arthritis, andpsoriasis. Folkman et al., J. Biol. Chem., 267:10931-10934 (1992);Klagsbrun et al., Annu. Rev. Physiol. 53:217-239 (1991); and Garner A.,“Vascular diseases”, In: Pathobiology of Ocular Disease. A DynamicApproach, Garner A., Klintworth G K, eds., 2nd Edition (Marcel Dekker,N.Y., 1994), pp 1625-1710.

In the case of tumor growth, angiogenesis appears to be crucial for thetransition from hyperplasia to neoplasia, and for providing nourishmentfor the growth and metastasis of the tumor. Folkman et al., Nature339:58 (1989). The neovascularization allows the tumor cells to acquirea growth advantage and proliferative autonomy compared to the normalcells. A tumor usually begins as a single aberrant cell which canproliferate only to a size of a few cubic millimeters due to thedistance from available capillary beds, and it can stay ‘dormant’without further growth and dissemination for a long period of time. Sometumor cells then switch to the angiogenic phenotype to activateendothelial cells, which proliferate and mature into new capillary bloodvessels. These newly formed blood vessels not only allow for continuedgrowth of the primary tumor, but also for the dissemination andrecolonization of metastatic tumor cells. Accordingly, a correlation hasbeen observed between density of microvessels in tumor sections andpatient survival in breast cancer as well as in several other tumors.Weidner et al., N. Engl. J. Med 324:1-6 (1991); Horak et al., Lancet340:1120-1124 (1992); Macchiarini et al., Lancet 340:145-146 (1992). Theprecise mechanisms that control the angiogenic switch is not wellunderstood, but it is believed that neovascularization of tumor massresults from the net balance of a multitude of angiogenesis stimulatorsand inhibitors (Folkman, 1995, Nat Med 1(1):27-31).

The process of vascular development is tightly regulated. To date, asignificant number of molecules, mostly secreted factors produced bysurrounding cells, have been shown to regulate EC differentiation,proliferation, migration and coalescence into cord-like structures. Forexample, vascular endothelial growth factor (VEGF) has been identifiedas the key factor involved in stimulating angiogenesis and in inducingvascular permeability. Ferrara et al., Endocr. Rev. 18:4-25 (1997). Thefinding that the loss of even a single VEGF allele results in embryoniclethality points to an irreplaceable role played by this factor in thedevelopment and differentiation of the vascular system. Furthermore,VEGF has been shown to be a key mediator of neovascularizationassociated with tumors and intraocular disorders. Ferrara et al.,Endocr. Rev. supra. The VEGF mRNA is overexpressed by the majority ofhuman tumors examined. Berkman et al., J. Clin. Invest. 91:153-159(1993); Brown et al., Human Pathol. 26:86-91 (1995); Brown et al.,Cancer Res. 53:4727-4735 (1993); Mattern et al., Brit. J. Cancer73:931-934 (1996); Dvorak et al., Am. J. Pathol. 146:1029-1039 (1995).

Also, the concentration levels of VEGF in eye fluids are highlycorrelated to the presence of active proliferation of blood vessels inpatients with diabetic and other ischemia-related retinopathies. Aielloet al., N. Engl. J. Med. 331:1480-1487 (1994). Furthermore, studies havedemonstrated the localization of VEGF in choroidal neovascular membranesin patients affected by AMD. Lopez et al., Invest. Ophthalmol. Vis. Sci.37:855-868 (1996).

Anti-VEGF neutralizing antibodies suppress the growth of a variety ofhuman tumor cell lines in nude mice (Kim et al., Nature 362:841-844(1993); Warren et al., J. Clin. Invest. 95:1789-1797 (1995); Borgströmet al., Cancer Res. 56:40324039 (1996); Melnyk et al., Cancer Res.56:921-924 (1996)) and also inhibit intraocular angiogenesis in modelsof ischemic retinal disorders. Adamis et al., Arch. Ophthalmol.114:66-71 (1996). Therefore, anti-VEGF monoclonal antibodies or otherinhibitors of VEGF action are promising candidates for the treatment oftumors and various intraocular neovascular disorders. Such antibodiesare described, for example, in EP 817,648 published Jan. 14, 1998; andin W098/45331 and W098/45332, both published Oct. 15, 1998. One of theanti-VEGF antibodies, bevacizumab, has been approved by the FDA for usein combination with a chemotherapy regimen to treat metastaticcolorectal cancer (CRC). And bevacizumab is being investigated in manyongoing clinical trials for treating various cancer indications.

It is known that extracellular matrix (ECM) plays an important roleduring the process of angiogenesis. Madri, Transpl. Immunol. 5:179-83(1997). ECs are surrounded by provisional ECM during their migration,and adhere to newly synthesized vascular basement membranes afterforming a lumen. In addition to providing a scaffold during capillarymorphogenesis, the ECM has been shown to exert complex local controls onthe functions of ECs. For example, the ECM is able to regulate theavailability of soluble angiogenic mediators to ECs and specify thenature and type of interactions with integrin and cellular adhesionmolecules. It has also been suggested that EC survival is regulated bycooperation between growth factor receptors and integrins, which are inturn governed by the composition of the local ECM. Stupack and Cheresh,Oncogene 22:9022-29 (2003).

Despite the many advances in the field of angiogenesis, some of thesteps during vessel tube formation are still poorly defined.Particularly, little is known about how tubulogenesis is regulated—howvascular cords progress to become tubes, and what factors regulate thistransition. In view of the role of angiogenesis in many diseases anddisorders, it is desirable to have a means of reducing or inhibiting oneor more of the biological effects causing these processes. It is alsodesirable to have a means of assaying for the presence of pathogenicpolypeptides in normal and diseased conditions, and especially cancer.There also exists the need to identify targets and develop means thatcan enhance the efficacy of existing anti-angiogenesis therapies.

SUMMARY OF THE INVENTION

The present invention is based on the identification andcharacterization of a novel EC-derived secreted factor, EGF-like domain7 (EGFL7). EGFL7 is expressed at high levels in the vasculatureassociated with tissue proliferation, and is down-regulated in most ofthe mature vessels in normal adult tissues. Loss of EGFL7 functioncaused significant vascular defects in animal embryos, and reduced tumorgrowth. Based on its structure, expression and activity, EGFL7 isconsidered a novel ECM molecule. Furthermore, EGFL7 is found to supportEC adhesion and migration, and is implicated in playing a supportingrole to angiogenic factors in tumor angiogenesis. EGFL7 antagonists, onthe other hand, were found to effectively block EGFL7-associated ECadhesion and migration. Accordingly, the present invention providesnovel compositions and uses thereof for modulating (e.g., promoting orinhibiting) processes involved in angiogenesis.

In one embodiment, the present invention provides a compositioncomprising an EGFL7 antagonist in admixture with a pharmaceuticallyacceptable carrier. In one aspect, the composition comprises atherapeutically effective amount of the antagonist. In another aspect,the composition comprises a further active ingredient, for example, ananti-angiogenic agent. Preferably, the composition is sterile. The EGFL7antagonist may be administered in the form of a liquid pharmaceuticalformulation, which may be preserved to achieve extended storagestability. Preserved liquid pharmaceutical formulations might containmultiple doses of EGFL7 antagonist, and might, therefore, be suitablefor repeated use. In a preferred embodiment, where the compositioncomprises an antibody, the antibody is a monoclonal antibody, anantibody fragment, a humanized antibody, or a single-chain antibody.

In another embodiment, the present invention provides a method forpreparing such a composition useful for the treatment of an angiogenesisassociated disorder comprising admixing a therapeutically effectiveamount of an EGFL7 antagonist with a pharmaceutically acceptablecarrier.

In a still further aspect, the present invention provides an article ofmanufacture comprising:

(a) a composition of matter comprising an EGFL7 antagonist;

(b) a container containing said composition; and

(c) a label affixed to said container, or a package insert included insaid container referring to the use of said EGFL7 antagonist in thetreatment of an angiogenesis associated disorder, wherein the antagonistmay be an antibody which binds to the EGFL7 and blocks its activity. Thecomposition may comprise a therapeutically effective amount of the EGFL7antagonist.

In another embodiment, the invention provides a method for identifying acompound that inhibits the activity of an EGFL7 polypeptide comprisingcontacting a test compound with an EGFL7 polypeptide under conditionsand for a time sufficient to allow the test compound and polypeptide tointeract and determining whether the activity of the EGFL7 polypeptideis inhibited. In a specific preferred aspect, either the test compoundor the EGFL7 polypeptide is immobilized on a solid support. In anotherpreferred aspect, the non-immobilized component carries a detectablelabel. In a preferred aspect, this method comprises the steps of:

(a) contacting cells and a test compound to be screened in the presenceof an EGFL7 polypeptide under conditions suitable for the induction of acellular response normally induced by an EGFL7 polypeptide; and

(b) determining the induction of said cellular response to determine ifthe test compound is an effective antagonist.

In another preferred aspect, this process comprises the steps of:

(a) contacting cells and a test compound to be screened in the presenceof an EGFL7 polypeptide under conditions suitable for the stimulation ofcell proliferation by an EGFL7 polypeptide; and

(b) measuring the proliferation of the cells to determine if the testcompound is an effective antagonist.

One type of antagonist of an EGFL7 polypeptide that inhibits one or moreof the functions or activities of the EGFL7 polypeptide is an antibody.Hence, in another aspect, the invention provides an isolated antibodythat binds an EGFL7 polypeptide. In a preferred aspect, the antibody isa monoclonal antibody, which preferably has non-humancomplementarity-determining-region (CDR) residues and humanframework-region (FR) residues. The antibody may be labeled and may beimmobilized on a solid support. In a further aspect, the antibody is anantibody fragment, a single-chain antibody, a humanized antibody, or ahuman antibody. Preferably, the antibody specifically binds to thepolypeptide.

In a still further aspect, the invention provides a method of diagnosinga cardiovascular, endothelial or angiogenic disorder in a mammal whichcomprises analyzing the level of expression of a gene encoding an EGFL7polypeptide (a) in a test sample of tissue cells obtained from saidmammal, and (b) in a control sample of known normal tissue cells of thesame cell type, wherein a higher or lower expression level in the testsample as compared to the control sample is indicative of the presenceof a cardiovascular, endothelial or angiogenic disorder in said mammal.The expression of a gene encoding an EGFL7 polypeptide may optionally beaccomplished by measuring the level of mRNA or the polypeptide in thetest sample as compared to the control sample.

In a still further aspect, the present invention provides a method ofdiagnosing a cardiovascular, endothelial or angiogenic disorder in amammal which comprises detecting the presence or absence of an EGFL7polypeptide in a test sample of tissue cells obtained from said mammal,wherein the presence or absence of said EGFL7 polypeptide in said testsample is indicative of the presence of a cardiovascular, endothelial orangiogenic disorder in said mammal.

In a still further embodiment, the invention provides a method ofdiagnosing a cardiovascular, endothelial or angiogenic disorder in amammal comprising (a) contacting an anti-EGFL7 antibody with a testsample of tissue cells obtained from the mammal, and (b) detecting theformation of a complex between the antibody and the EGFL7 polypeptide inthe test sample, wherein the formation of said complex is indicative ofthe presence of a cardiovascular, endothelial or angiogenic disorder inthe mammal. The detection may be qualitative or quantitative, and may beperformed in comparison with monitoring the complex formation in acontrol sample of known normal tissue cells of the same cell type. Alarger or smaller quantity of complexes formed in the test sampleindicates the presence of a cardiovascular, endothelial or angiogenicdysfunction in the mammal from which the test tissue cells wereobtained. The antibody preferably carries a detectable label. Complexformation can be monitored, for example, by light microscopy, flowcytometry, fluorimetry, or other techniques known in the art. The testsample is usually obtained from an individual suspected to have acardiovascular, endothelial or angiogenic disorder.

In another embodiment, the invention provides a method for determiningthe presence of an EGFL7 polypeptide in a sample comprising exposing asample suspected of containing the EGFL7 polypeptide to an anti-EGFL7antibody and determining binding of said antibody to a component of saidsample. In a specific aspect, the sample comprises a cell suspected ofcontaining the EGFL7 polypeptide and the antibody binds to the cell. Theantibody is preferably detectably labeled and/or bound to a solidsupport.

In further aspects, the invention provides a cardiovascular, endothelialor angiogenic disorder diagnostic kit comprising an anti-EGFL7 antibodyand a carrier in suitable packaging. Preferably, such kit furthercomprises instructions for using said antibody to detect the presence ofthe EGFL7 polypeptide. Preferably, the carrier is a buffer, for example.Preferably, the cardiovascular, endothelial or angiogenic disorder iscancer.

In yet another embodiment, the present invention provides a method ofreducing or inhibiting angiogenesis in a subject having a pathologicalcondition associated with angiogenesis, comprising administering to thesubject an EGFL7 antagonist capable of interfering with EGFL7-inducedendothelial cell migration, thereby reducing or inhibiting angiogenesisin the subject. Preferably the EGFL7 antagonist is an anti-EGFL7antibody. The antagonist's ability to interfere with EGFL7-induced ECmigration can be detected, for example, in an in vitro cell migrationassay.

In one preferred embodiment, the pathological condition associated withangiogenesis is a cancer. In another preferred embodiment, thepathological condition associated with angiogenesis is an intraocularneovascular disease. In yet another preferred embodiment, the EGFL7antagonist is co-administered with another anti-angiogenic agent, suchas an anti-VEGF antibody including bevacizumab. The present inventionalso provides a method of enhancing the efficacy of an anti-angiogenicagent treatment in a subject having a pathological condition associatedwith angiogenesis, comprising administering to the subject an EGFL7antagonist in combination with the anti-angiogenic agent. Such a methodwill be useful in treating cancers or intraocular neovascular diseases,especially those diseases or stages of the diseases that respondedpoorly to a treatment with the anti-angiogenic agent alone. Theanti-angiogenic agent can be any agent capable of reducing or inhibitingangiogenesis, including VEGF antagonists such as anti-VEGF antibody.When treating tumor, the EGFL7 antagonist alone or in combination withan anti-angiogenic agent can be further combined with a chemotherapyregime comprising one or more chemotherapeutic agents. Radioactivetherapy can also be combined for enhanced efficacy.

In yet another embodiment, the invention provides a method for promotingvascular formation in a mammal comprising administering to the mammal anEGFL7 polypeptide or an agonist of an EGFL7 polypeptide, whereinvascular formation in said mammal is stimulated. Preferably, the mammalis human.

In yet another embodiment, the invention provides a method forstimulating angiogenesis in a mammal comprising administering atherapeutically effective amount of an EGFL7 polypeptide or agonistthereof to the mammal. Preferably, the mammal is a human, and morepreferably angiogenesis would promote tissue regeneration or woundhealing.

In yet another embodiment, the invention provides a method formodulating (e.g., inhibiting or stimulating) vascular tube formation ina mammal comprising administering to the mammal a composition comprisingan EGFL7 polypeptide, agonist or antagonist thereof.

In yet another embodiment, the invention provides a method formodulating (e.g., inducing or reducing) angiogenesis by modulating(e.g., inducing or reducing) endothelial cell migration in a mammalcomprising administering to the mammal an EGFL7 polypeptide, agonist orantagonist thereof, wherein endothelial cell migration in said mammal ismodulated.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1 a and 1 b show that EGFL7 is conserved during vertebrateevolution. a: Amino acid alignment among human, mouse, xenopus andzebrafish EGFL7s. The EGFL7 gene encodes a putative secreted protein of˜30 kD. The human (Homo sapiens) amino acid sequence shares 77.45%,47.14% and 42.96% homology to that of the mouse (Mus musculus), frog(Xenopus laevis) and zebrafish (Danio rerio), respectively. Structuralanalysis using a number of algorithms predicts that the EGFL7 proteinscontain the following domains (in boxes starting from the N′-terminus):a signal sequence, an EMI domain a, two EGF-like domains in the centralportion, followed by a leucine and valine rich C-terminal region. b:Zebrafish EGFL7 cDNA, amino acid, and an intron sequence. Arrowed linesindicate the two antisense oligos, AS₋₄₇ and AS₉₅, and the PCR primersused to detect intron retention.

FIGS. 2 a-2 n depict EGFL7 expression profile. EGFL7 whole mount in situhybridization on mouse (a-b) and zebrafish (j-n) embryos. b:cross-section of a stained with nuclear-fast-red. RBC=red blood cells.j-m: light arrow=lateral plate mesoderm, dark arrow=dorsal aorta, darkarrowhead=ISVs. Inset: close-up of the trunk. n: cloche mutant.so=somite. c: pregnant mouse uterus stained for EGFL7 and PECAM.Bracket=decidua. d-i: Radioactive in situ hybridization (g-i) and H&E(d-f) on human lung sections. Scale bar: 0.45 mm (a, m, n), 0.07 mm (b),0.38 mm (c-i), 0.25 mm (j, 1), 0.15 mm (k), 0.26 mm (m inset), and 0.04mm (c inset).

FIGS. 3 a-3 d show that EGFL7 gene knockdown causes vasculartubulogenesis defect in zebrafish embryos. Zebrafish embryos injectedwith control (Con₋₄₇ or Con₁₉₅) or EGFL7antisense (AS₋₄₇ or AS₁₉₅)oligos. a: Gross morphology at 48 hpf. Arrow points to pericardialedema, arrowhead indicates hemorrhage. b-d:fliI expression at 23 hpf (b)and 30 hpf (c-d). d: Close up view of the mid trunk vasculatures boxedin c. White arrowhead: lumen of the dorsal aorta, black arrowhead: lumenof the posterior cardinal vein, black arrow: intersegmental vessels.Scale bar: 0.6 mm (a), 0.23 mm (d) and 0.5 mm (b, c).

FIGS. 4 a-4 h depict that EC number is unaltered in the EGFL7 KDs.flkl:GFP transgenic fish injected with control (a, c, e, g) or antisense(b, d, f, h) oligos were analyzed at 22-somite (a-d) or 30hpf (e-h). a,b: Dorsal view. e, f: Lateral view. c, d, g, h: Cross sections taken atthe level indicated by white-lines in a-b, e-f were counter stained withphalloidin and DAPI. PD: pronephric ducts, So: somites, N: Notochords,white arrows: arterial ECs, white arrowheads=venous ECs, DA=dorsalaorta, PCV=posterior cardinal vein. Scale bar: 0.33 mm (a, b), 0.03 mm(c, d, g, h), 0.47 mm (e, f).

FIGS. 5 a-5 g show that EGFL7 promotes EC adhesion. Vinculin staining ofhuman umbilical-cord vascular endothelial cells (HUVEC) reveals focaladhesion formation on fibronectin (b), type I collagen (c), and EGFL7(d), but not BSA (a). Adhesion strength on EGFL7 is weaker than oncollagen or fibronectin since fewer cells remain adherent to the EGFL7substrate after spinning at 46 g (e). Dose-dependent blockage of HUVECadhesion to EGFL7 but not fibronectin by an anti-EGFL7 antibody confirmssubstrate specificity. A control antibody (anti-B7x) has no effect onany substrate (f). g: Kinetics of HUVEC adhesion on various substrates.Scale bar: 0.03 mm (a-d).

FIG. 6 depicts comparison of B16 melanoma tumor growth rates in theEGFL7^(−/−) homozygous (n=11) and the EGFL7^(+/−)heterozygous (n=11)knockout mice.

FIGS. 7 a-7 b depict comparisons of B16 melanoma tumor incidence andgrowth rate in the EGFL7^(−/−) homozygous knockout mice (n=10) versustheir wildtype littermates (n=13). In 7b, tumor free mice were excluded.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Definitions

Unless defined otherwise, technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. See, e.g. Singleton et al.,Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley &Sons (New York, N.Y. 1994); Sambrook et al., Molecular Cloning. ALaboratory Manual, Cold Springs Harbor Press (Cold Springs Harbor, NY1989). For purposes of the present invention, the following terms aredefined below.

As used herein, the terms “EGFL7” and “EGFL7 polypeptide,” which areused interchangeably, refer to native sequence EGFL7, EGFL7 variants,and chimeric EGFL7, each of which is defined herein. Optionally, theEGFL7 is not associated with native glycosylation. “Nativeglycosylation” refers to the carbohydrate moieties that are covalentlyattached to EGFL7 when it is produced in mammalian cells, particularlyin the cells in which it is produced in nature. Accordingly, human EGFL7produced in a non-human cell is an example of EGFL7 that may “not beassociated with native glycosylation.” Sometimes the EGFL7 may not beglycosylated at all, as in the case where it is produced in prokaryotes,e.g. E. coli.

EGFL7 nucleic acid is RNA or DNA that encodes an EGFL7 polypeptide, asdefined above, or which hybridizes to such DNA or RNA and remains stablybound to it under stringent hybridization conditions and is greater thanabout 10 nucleotides in length. Stringent conditions are those which (1)employ low ionic strength and high temperature for washing, for example,0.15 M NaC/0.015 M sodium citrate/0.1% NaDodSO₄ at 50° C., or (2) useduring hybridization a denaturing agent such as formamide, for example,50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1%polyvinlypyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mMNaCI, 75 mM sodium citrate at 42° C.

Nucleic acid is operably linked when it is placed into a functionalrelationship with another nucleic acid sequence. EGFL7 nucleic acid maybe operably linked with another nucleic acid sequence in a vector suchthat it may be expressed in a particular host organism. This may be doneby methods well known in the art. For example, DNA for a presequence ora secretory leader is operably linked to DNA for a polypeptide if it isexpressed as a preprotein that participates in the secretion of thepolypeptide; a promoter or enhancer is operably linked to a codingsequence if it affects the transcription of the sequence; or a ribosomebinding site is operably linked to a coding sequence if it is positionedso as to facilitate translation. Generally, “operably linked” means thatthe DNA sequences being linked are contiguous and, in the case of asecretory leader, contiguous and in reading phase. However, enhancers donot have to be contiguous. Linking is accomplished by ligation atconvenient restriction sites. If such sites do not exist, then syntheticoligonucleotide adapters or linkers are used in accord with conventionalpractice.

“Native sequence EGFL7” comprises a polypeptide having the same aminoacid sequence as EGFL7 derived from nature, regardless of its mode ofpreparation or species. Thus, native sequence EGFL7 can have the aminoacid sequence of naturally occurring human EGFL7, murine EGFL7, XenopusEGFL7, zebrafish EGFL7 or EGFL7 from any other species. For example apreferred full-length native sequence human EGFL7 amino acid sequence isshown in FIG. 1A (SEQ ID NO: 1). A native sequence mouse EGFL7 aminoacid sequence is shown in FIG. 1A (SEQ ID NO: 2). Such native sequenceEGFL7 can be isolated from nature or can be produced by recombinantand/or synthetic means. The term “native sequence EGFL7” specificallyencompasses naturally occurring prepro, pro and mature forms andtruncated forms of EGFL7, naturally occurring variant forms, andnaturally occurring allelic variants.

“EGFL7 variants” are biologically active EGFL7 polypeptides having anamino acid sequence which differs from the sequence of a native sequenceEGFL7 polypeptide, such as those shown in FIG. 1A (SEQ ID NOs: 1-4) forhuman, murine, Xenopus and zebrafish EGFL7 respectively, by virtue of aninsertion, deletion, modification and/or substitution of one or moreamino acid residues within the native sequence. EGFL7 variants generallyhave less than 100% sequence identity with a native sequence EGFL7, suchas the human EGFL7 of SEQ ID NO: 1. Ordinarily, however, a biologicallyactive EGFL7 variant will have an amino acid sequence with at leastabout 70% amino acid sequence identity with the amino acid sequence of anaturally occurring EGFL7 such as the human EGFL7 of SEQ ID NO: 1,preferably at least about 75%, more preferably at least about 80%, evenmore preferably at least about 85%, even more preferably at least about90%, with increasing preference of at least about 95% to at least about99% amino acid sequence identity, in 1% increments. The EGFL7 variantsinclude peptide fragments of at least 5 amino acids that retain abiological activity of the corresponding native sequence EGFL7polypeptide. EGFL7 variants also include EGFL7 polypeptides wherein oneor more amino acid residues are added at the N- or C-terminus of, orwithin, a native EGFL7 sequence. EGFL7 variants also include EGFL7polypeptides where a number of amino acid residues are deleted andoptionally substituted by one or more amino acid residues. EGFL7variants also may be covalently modified, for example by substitutionwith a moiety other than a naturally occurring amino acid or bymodifying an amino acid residue to produce a non-naturally occurringamino acid. EGFL7 variants may comprise a heparin binding domain.“Percent amino acid sequence identity” with respect to the EGFL7sequence is defined herein as the percentage of amino acid residues inthe candidate sequence that are identical with the residues in the EGFL7sequence, after aligning the sequences and introducing gaps, ifnecessary, to achieve the maximum percent sequence identity, and notconsidering any conservative substitutions as part of the sequenceidentity. None of N-terminal, C-terminal, or internal extensions,deletions or insertions into the candidate EGFL7 sequence shall beconstrued as affecting sequence identity or homology. Methods andcomputer programs for the alignment are well known in the art. One suchcomputer program is “ALIGN-2,” authored by Genentech, which has beenfiled with user documentation in the United States Copyright Office,Washington, D.C. 20559, where it is registered under U.S. CopyrightRegistration No. TXU510087.

A “chimeric EGFL7” molecule is a polypeptide comprising full-lengthEGFL7 or one or more domains thereof fused or bonded to heterologouspolypeptide. The chimeric EGFL7 molecule will generally share at leastone biological property in common with naturally occurring EGFL7. Anexample of a chimeric EGFL7 molecule is one that is epitope tagged forpurification purposes. Another chimeric EGFL7 molecule is an EGFL7immunoadhesin. “Isolated EGFL7” means EGFL7 that has been purified froman EGFL7 source or has been prepared by recombinant or synthetic methodsand purified. Purified EGFL7 is substantially free of other polypeptidesor peptides. “Substantially free” here means less than about 5%,preferably less than about 2%, more preferably less than about 1%, evenmore preferably less than about 0.5%, most preferably less than about 0.1% contamination with other source proteins. “Essentially pure” proteinmeans a composition comprising at least about 90% by weight of theprotein, based on total weight of the composition, preferably at leastabout 95% by weight, more preferably at least about 90% by weight, evenmore preferably at least about 95% by weight. “Essentially homogeneous”protein means a composition comprising at least about 99% by weight ofprotein, based on total weight of the composition.

The term “antagonist” is used in the broadest sense, and includes anymolecule that partially or fully blocks, inhibits, or neutralizes abiological activity of a native EGFL7 polypeptide. Suitable antagonistmolecules specifically include antagonist antibodies or antibodyfragments, fragments or amino acid sequence variants of native EGFL7polypeptides, peptides, soluble fragments of EGFL7 receptor(s), smallorganic molecules, etc. Methods for identifying agonists or antagonistsof an EGFL7 polypeptide may comprise contacting an EGFL7 polypeptidewith a candidate agonist or antagonist molecule and measuring adetectable change in one or more biological activities normallyassociated with the EGFL7 polypeptide. “Active” or “activity” for thepurposes herein refers to form(s) of EGFL7 which retain a biologicaland/or an immunological activity of native or naturally-occurring EGFL7,wherein “biological” activity refers to a biological function (eitherinhibitory or stimulatory) caused by a native or naturally-occurringEGFL7 other than the ability to induce the production of an antibodyagainst an antigenic epitope possessed by a native ornaturally-occurring EGFL7 and an “immunological” activity refers to theability to induce the production of an antibody against an antigenicepitope possessed by a native or naturally-occurring EGFL7.

Thus, “biologically active” when used in conjunction with “EGFL7” or“isolated EGFL7” or an agonist of EGFL7, means an EGFL7 polypeptide thatexhibits or shares an effector function of native sequence EGFL7. Aprincipal effector function of EGFL7 is its ability to promote vascularformation. Even more preferably, the biological activity is the abilityto regulate tubulogenesis.

“EGFL7 receptor” is a molecule to which EGFL7 binds and which mediatesthe biological properties of EGFL7.

The term “antibody” herein is used in the broadest sense andspecifically covers human, non-human (e.g. murine) and humanizedmonoclonal antibodies (including full length monoclonal antibodies),polyclonal antibodies, multispecific antibodies (e.g., bispecificantibodies), and antibody fragments so long as they exhibit the desiredbiological activity.

“Antibodies” (Abs) and “immunoglobulins” (Igs) are glycoproteins havingthe same structural characteristics. While antibodies exhibit bindingspecificity to a specific antigen, immunoglobulins include bothantibodies and other antibody-like molecules that lack antigenspecificity. Polypeptides of the latter kind are, for example, producedat low levels by the lymph system and at increased levels by myelomas.

“Native antibodies” and “native immunoglobulins” are usuallyheterotetrameric glycoproteins of about 150,000 daltons, composed of twoidentical light (L) chains and two identical heavy (H) chains. Eachlight chain is linked to a heavy chain by one covalent disulfide bond,while the number of disulfide linkages varies among the heavy chains ofdifferent immunoglobulin isotypes. Each heavy and light chain also hasregularly spaced intra-chain disulfide bridges. Each heavy chain has atone end a variable domain (V_(H)) followed by a number of constantdomains. Each light chain has a variable domain at one end (V_(L)) and aconstant domain at its other end; the constant domain of the light chainis aligned with the first constant domain of the heavy chain, and thelight-chain variable domain is aligned with the variable domain of theheavy chain. Particular amino acid residues are believed to form aninterface between the light- and heavy-chain variable domains.

The term “variable” refers to the fact that certain portions of thevariable domains differ extensively in sequence among antibodies and areused in the binding and specificity of each particular antibody for itsparticular antigen. However, the variability is not evenly distributedthroughout the variable domains of antibodies. It is concentrated inthree segments called hypervariable regions both in the light chain andthe heavy chain variable domains. The more highly conserved portions ofvariable domains are called the framework region (FR). The variabledomains of native heavy and light chains each comprise four FRs (FR1,FR2, FR3 and FR4, respectively), largely adopting a β-sheetconfiguration, connected by three hypervariable regions, which formloops connecting, and in some cases forming part of, the β-sheetstructure. The hypervariable regions in each chain are held together inclose proximity by the FRs and, with the hypervariable regions from theother chain, contribute to the formation of the antigen-binding site ofantibodies (see Kabat et al., Sequences of Proteins of ImmunologicalInterest 5th Ed. Public Health Service, National Institutes of Health,Bethesda, Md. (1991), pages 647-669). The constant domains are notinvolved directly in binding an antibody to an antigen, but exhibitvarious effector functions, such as participation of the antibody inantibody-dependent cellular toxicity.

The term “hypervariable region” when used herein refers to the aminoacid residues of an antibody which are responsible for antigen binding.The hypervariable region comprises amino acid residues from a“complementarity determining region” or “CDR” (i.e. residues 24-34 (L1),50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35(H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain;Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed.Public Health Service, National Institutes of Health, Bethesda, Md.(1991)) and/or those residues from a “hypervariable loop” (i.e. residues26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chain variable domainand 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy chain variabledomain; Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)). “Framework”or “FR” residues are those variable domain residues other than thehypervariable region residues as herein defined.

Papain digestion of antibodies produces two identical antigen-bindingfragments, called “Fab” fragments, each with a single antigen-bindingsite, and a residual “Fc” fragment, whose name reflects its ability tocrystallize readily. Pepsin treatment yields an F(ab′)₂ fragment thathas two antigen-combining sites and is still capable of cross-linkingantigen.

“Fv” is the minimum antibody fragment that contains a completeantigen-recognition and -binding site. This region consists of a dimerof one heavy chain and one light chain variable domain in tight,non-covalent association. It is in this configuration that the threehypervariable regions of each variable domain interact to define anantigen-binding site on the surface of the V_(H)-V_(L) dimer.Collectively, the six hypervariable regions confer antigen-bindingspecificity to the antibody. However, even a single variable domain (orhalf of an Fv comprising only three hypervariable regions specific foran antigen) has the ability to recognize and bind antigen, although at alower affinity than the entire binding site.

The Fab fragment also contains the constant domain of the light chainand the first constant domain (CH1) of the heavy chain. Fab′ fragmentsdiffer from Fab fragments by the addition of a few residues at thecarboxyl terminus of the heavy chain CH1 domain including one or morecysteine(s) from the antibody hinge region. Fab′-SH is the designationherein for Fab′ in which the cysteine residue(s) of the constant domainsbear a free thiol group. F(ab′)₂ antibody fragments originally wereproduced as pairs of Fab′ fragments which have hinge cysteines betweenthem. Other chemical couplings of antibody fragments are also known.

The “light chains” of antibodies (immunoglobulins) from any vertebratespecies can be assigned to one of two clearly distinct types, calledkappa (κ) and lambda (λ), based on the amino acid sequences of theirconstant domains.

Depending on the amino acid sequence of the constant domain of theirheavy chains, immunoglobulins can be assigned to different classes.There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, andIgM, and several of these may be further divided into subclasses(isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. Theheavy-chain constant domains that correspond to the different classes ofimmunoglobulins are called a, α, β, γ, and μ, respectively. The subunitstructures and three-dimensional configurations of different classes ofimmunoglobulins are well known.

“Antibody fragments” comprise a portion of a full-length antibody,generally the antigen binding or variable domain thereof. Examples ofantibody fragments include Fab, Fab′, F(ab′)₂, and Fv fragments;diabodies; linear antibodies; single-chain antibody molecules; andmulti-specific antibodies formed from antibody fragments.

The term “monoclonal antibody” as used herein refers to an antibodyobtained from a population of substantially homogeneous antibodies,i.e., the individual antibodies comprising the population are identicalexcept for possible naturally occurring mutations that may be present inminor amounts. Monoclonal antibodies are highly specific, being directedagainst a single antigenic site. Furthermore, in contrast toconventional (polyclonal) antibody preparations that typically includedifferent antibodies directed against different determinants (epitopes),each monoclonal antibody is directed against a single determinant on theantigen. The modifier “monoclonal” indicates the character of theantibody as being obtained from a substantially homogeneous populationof antibodies, and is not to be construed as requiring production of theantibody by any particular method. For example, the monoclonalantibodies to be used in accordance with the present invention may bemade by the hybridoma method first described by Kohler et al., Nature256:495 (1975), or may be made by recombinant DNA methods (see, e.g.,U.S. Pat. No. 4,816,567). The “monoclonal antibodies” may also beisolated from phage antibody libraries using the techniques described inClackson et al., Nature 352:624-628 (1991) and Marks et al., J. Mol.Biol. 222:581-597 (1991), for example.

The monoclonal antibodies herein specifically include “chimeric”antibodies (immunoglobulins) in which a portion of the heavy and/orlight chain is identical with or homologous to corresponding sequencesin antibodies derived from a particular species or belonging to aparticular antibody class or subclass, while the remainder of thechain(s) is identical with or homologous to corresponding sequences inantibodies derived from another species or belonging to another antibodyclass or subclass, as well as fragments of such antibodies, so long asthey exhibit the desired biological activity (U.S. Pat. No. 4,816,567;and Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984)).

“Humanized” forms of non-human (e.g., murine) antibodies are chimericantibodies that contain minimal sequence derived from non-humanimmunoglobulin. For the most part, humanized antibodies are humanimmunoglobulins (recipient antibody) in which hypervariable regionresidues of the recipient are replaced by hypervariable region residuesfrom a non-human species (donor antibody) such as mouse, rat, rabbit ornon-human primate having the desired specificity, affinity, andcapacity. In some instances, framework region (FR) residues of the humanimmunoglobulin are replaced by corresponding non-human residues.Furthermore, humanized antibodies may comprise residues that are notfound in the recipient antibody or in the donor antibody. Thesemodifications are made to further refine antibody performance. Ingeneral, the humanized antibody will comprise substantially all of atleast one, and typically two, variable domains, in which all orsubstantially all of the hypervariable regions correspond to those of anon-human immunoglobulin and all or substantially all of the FRs arethose of a human immunoglobulin sequence. The humanized antibodyoptionally also will comprise at least a portion of an immunoglobulinconstant region (Fc), typically that of a human immunoglobulin. Forfurther details, see Jones et al. Nature 321:522-525 (1986); Reichmannet al. Nature 332:323-329 (1988); and Presta Curr. Op. Struct. Biol.2:593-596 (1992).

“Single-chain Fv” or “sFv” antibody fragments comprise the V_(H) andV_(L) domains of antibody, wherein these domains are present in a singlepolypeptide chain. Generally, the Fv polypeptide further comprises apolypeptide linker between the V_(H) and V_(L) domains which enables thesFv to form the desired structure for antigen binding. For a review ofsFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol.113, Rosenburg and Moore eds. Springer-Verlag, New York, pp. 269-315(1994).

The term “diabodies” refers to small antibody fragments with twoantigen-binding sites, which fragments comprise a heavy chain variabledomain (V_(H)) connected to a light chain variable domain (V_(L)) in thesame polypeptide chain (V_(H)-V_(L)). By using a linker that is tooshort to allow pairing between the two domains on the same chain, thedomains are forced to pair with the complementary domains of anotherchain and create two antigen-binding sites. Diabodies are described morefully in, for example, EP 404,097; WO 93/11161; and Hollinger et al.Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993).

The expression “linear antibodies” when used throughout this applicationrefers to the antibodies described in Zapata et al. Protein Eng.8(10):1057-1062 (1995). Briefly, these antibodies comprise a pair oftandem Fd segments (V_(H)-C_(H)1-V_(H)-C_(H)1) which form a pair ofantigen binding regions. Linear antibodies can be bispecific ormonospecific.

The term “epitope” is used to refer to binding sites for (monoclonal orpolyclonal) antibodies on protein antigens.

By “agonist antibody” is meant an antibody that is an EGFL7 agonist andthus possesses one or more of the biological properties of nativesequence EGFL7.

The term “EGFL7 immunoadhesin” is used interchangeably with the term“EGFL7-immunoglobulin chimera”, and refers to a chimeric molecule thatcombines at least a portion of an EGFL7 molecule (native or variant)with an immunoglobulin sequence. The immunoglobulin sequence preferably,but not necessarily, is an immunoglobulin constant domain.Immunoadhesins can possess many of the valuable chemical and biologicalproperties of human antibodies. Since immunoadhesins can be constructedfrom a human protein sequence with a desired specificity linked to anappropriate human immunoglobulin hinge and constant domain (Fc)sequence, the binding specificity of interest can be achieved usingentirely human components. Such immunoadhesins are minimally immunogenicto the patient, and are safe for chronic or repeated use.

Examples of homomultimeric immunoadhesins which have been described fortherapeutic use include the CD4-IgG immunoadhesin for blocking thebinding of HIV to cell-surface CD4. Data obtained from Phase I clinicaltrials, in which CD4-IgG was administered to pregnant women just beforedelivery, suggests that this immunoadhesin may be useful in theprevention of maternal-fetal transfer of HIV (Ashkenazi et al., Intern.Rev. Immunol. 10:219-227 (1993)). An immunoadhesin which binds tumornecrosis factor (TNF) has also been developed. TNF is a proinflammatorycytokine which has been shown to be a major mediator of septic shock.Based on a mouse model of septic shock, a TNF receptor immunoadhesin hasshown promise as a candidate for clinical use in treating septic shock(Ashkenazi, A. et al. PNAS USA 88:10535-10539 (1991)). ENBREL®(etanercept), an immunoadhesin comprising a TNF receptor sequence fusedto an IgG Fc region, was approved by the U.S. Food and DrugAdministration (FDA), on Nov. 2, 1998, for the treatment of rheumatoidarthritis. The new expanded use of ENBREL® in the treatment ofrheumatoid arthritis was approved by FDA on Jun. 6, 2000. For recentinformation on TNF blockers, including ENBREL®, see Lovell et al., N.Engl. J. Med. 342:763-169 (2000), and accompanying editorial onp810-811; and Weinblatt et al., N. Engl. J. Med. 340:253-259 (1999);reviewed in Maini and Taylor, Annu. Rev. Med. 51:207-229 (2000).

If the two arms of the immunoadhesin structure have differentspecificities, the immunoadhesin is called a “bispecific immunoadhesin”by analogy to bispecific antibodies. Dietsch et al., J. Immunol. Methods162:123 (1993) describe such a bispecific immunoadhesin combining theextracellular domains of the adhesion molecules, E-selectin andP-selectin, each of which selectins is expressed in a different celltype in nature. Binding studies indicated that the bispecificimmunoglobulin fusion protein so formed had an enhanced ability to bindto a myeloid cell line compared to the monospecific immunoadhesins fromwhich it was derived.

The term “heteroadhesin” is used interchangeably with the expression“chimeric heteromultimer adhesin” and refers to a complex of chimericmolecules (amino acid sequences) in which each chimeric moleculecombines a biologically active portion, such as the extracellular domainof each of the heteromultimeric receptor monomers, with amultimerization domain. The “multimerization domain” promotes stableinteraction of the chimeric molecules within the heteromultimer complex.The multimerization domains may interact via an immunoglobulin sequence,leucine zipper, a hydrophobic region, a hydrophilic region, or a freethiol that forms an intermolecular disulfide bond between the chimericmolecules of the chimeric heteromultimer. The multimerization domain maycomprise an immunoglobulin constant region. In addition amultimerization region may be engineered such that steric interactionsnot only promote stable interaction, but further promote the formationof heterodimers over homodimers from a mixture of monomers.“Protuberances” are constructed by replacing small amino acid sidechains from the interface of the first polypeptide with larger sidechains (e.g. tyrosine or tryptophan). Compensatory “cavities” ofidentical or similar size to the protuberances are optionally created onthe interface of the second polypeptide by replacing large amino acidside chains with smaller ones (e.g. alanine or threonine). Theimmunoglobulin sequence preferably, but not necessarily, is animmunoglobulin constant domain. The immunoglobulin moiety in thechimeras of the present invention may be obtained from IgG₁, IgG₂, IgG₃or IgG₄ subtypes, IgA, IgE, IgD or IgM, but preferably IgG₁ or IgG₃.

As used herein, “treatment” is an approach for obtaining beneficial ordesired clinical results. For purposes of this invention, beneficial ordesired clinical results include, but are not limited to, alleviation ofsymptoms, diminishment of extent of disease, stabilized (i.e., notworsening) state of disease, delay or slowing of disease progression,amelioration or palliation of the disease state, and remission (whetherpartial or total), whether detectable or undetectable. “Treatment” canalso mean prolonging survival as compared to expected survival if notreceiving treatment. “Treatment” is an intervention performed with theintention of preventing the development or altering the pathology of adisorder. Accordingly, “treatment” refers to both therapeutic treatmentand prophylactic or preventative measures. Those in need of treatmentinclude those already with the disorder as well as those in which thedisorder is to be prevented. Specifically, the treatment may directlyprevent, slow down or otherwise decrease the pathology of cellulardegeneration or damage, such as the pathology of tumor cells in cancertreatment, or may render the cells more susceptible to treatment byother therapeutic agents.

“Chronic” administration refers to administration of the agent(s) in acontinuous mode as opposed to an acute mode, so as to maintain theinitial therapeutic effect (activity) for an extended period of time.“Intermittent” administration is treatment that is not consecutivelydone without interruption, but rather is cyclic in nature.

“Mammal” for purposes of treatment refers to any animal classified as amammal, including humans, other higher primates, domestic and farmanimals, and zoo, sports, or pet animals, such as dogs, cats, cattle,horses, sheep, pigs, goats, rabbits, etc. Preferably, the mammal ishuman.

“Tumor”, as used herein, refers to all neoplastic cell growth andproliferation, whether malignant or benign, and all pre-cancerous andcancerous cells and tissues.

The terms “cancer” and “cancerous” refer to or describe thephysiological condition in mammals that is typically characterized byunregulated cell growth. Examples of cancer include but are not limitedto, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. Moreparticular examples of such cancers include squamous cell cancer, lungcancer (including small-cell lung cancer, non-small cell lung cancer,adenocarcinoma of the lung, and squamous carcinoma of the lung), cancerof the peritoneum, hepatocellular cancer, gastric or stomach cancer(including gastrointestinal cancer), pancreatic cancer, glioblastoma,cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma,breast cancer, colon cancer, colorectal cancer, endometrial or uterinecarcinoma, salivary gland carcinoma, kidney or renal cancer, livercancer, prostate cancer, vulval cancer, thyroid cancer, hepaticcarcinoma and various types of head and neck cancer, as well as B-celllymphoma (including low grade/follicular non-Hodgkin's lymphoma (NHL);small lymphocytic (SL) NHL; intermediate grade/follicular NHL;intermediate grade diffuse NHL; high grade immunoblastic NHL; high gradelymphoblastic NHL; high grade small non-cleaved cell NHL; bulky diseaseNHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom'sMacroglobulinemia); chronic lymphocytic leukemia (CLL); acutelymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblasticleukemia; and post-transplant lymphoproliferative disorder (PTLD), aswell as abnormal vascular proliferation associated with phakomatoses,edema (such as that associated with brain tumors), and Meigs' syndrome.

A “chemotherapeutic agent” is a chemical compound useful in thetreatment of cancer. Examples of chemotherapeutic agents includealkylating agents such as thiotepa and CYTOXAN® cyclosphosphamide; alkylsulfonates such as busulfan, improsulfan and piposulfan; aziridines suchas benzodopa, carboquone, meturedopa, and uredopa; ethylenimines andmethylamelamines including altretamine, triethylenemelamine,trietylenephosphoramide, triethiylenethiophosphoramide andtrimethylolomelamine; acetogenins (especially bullatacin andbullatacinone); a camptothecin (including the synthetic analoguetopotecan); bryostatin; callystatin; CC-1065 (including its adozelesin,carzelesin and bizelesin synthetic analogues); cryptophycins(particularly cryptophycin 1 and cryptophycin 8); dolastatin;duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1);eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogenmustards such as chlorambucil, chlornaphazine, cholophosphamide,estramustine, ifosfamide, mechlorethamine, mechlorethamine oxidehydrochloride, melphalan, novembichin, phenesterine, prednimustine,trofosfamide, uracil mustard; nitrosureas such as carmustine,chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine;antibiotics such as the enediyne antibiotics (e. g., calicheamicin,especially calicheamicin gamma1I and calicheamicin omegaI1 (see, e.g.,Agnew, Chem Intl. Ed. Engl. 33:183-186 (1994)); dynemicin, includingdynemicin A; bisphosphonates, such as clodronate; an esperamicin; aswell as neocarzinostatin chromophore and related chromoprotein enediyneantiobiotic chromophores), aclacinomysins, actinomycin, authramycin,azaserine, bleomycins, cactinomycin, carabicin, carminomycin,carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin,6-diazo-5-oxo-L-norleucine, ADRIAMYCIN® doxorubicin (includingmorpholino-doxorubicin, cyanomorpholino-doxorubicin,2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin,idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolicacid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin,quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin,ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexateand 5-fluorouracil (5-FU); folic acid analogues such as denopterin,methotrexate, pteropterin, trimetrexate; purine analogs such asfludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidineanalogs such as ancitabine, azacitidine, 6-azauridine, carmofur,cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine;androgens such as calusterone, dromostanolone propionate, epitiostanol,mepitiostane, testolactone; anti-adrenals such as aminoglutethimide,mitotane, trilostane; folic acid replenisher such as frolinic acid;aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil;amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine;diaziquone; elfornithine; elliptinium acetate; an epothilone; etoglucid;gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids suchas maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol;nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone;podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK® polysaccharidecomplex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin;sizofiran; spirogermanium; tenuazonic acid; triaziquone;2,2′,2″-trichlorotriethylamine; trichothecenes (especially T-2 toxin,verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine;mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine;arabinoside (“Ara-C”); cyclophosphamide; thiotepa; taxoids, e.g., TAXOL®paclitaxel (Bristol-Myers Squibb Oncology, Princeton, N.J.), ABRAXANE™Cremophor-free, albumin-engineered nanoparticle formulation ofpaclitaxel (American Pharmaceutical Partners, Schaumberg, Ill.), andTAXOTERE® doxetaxel (Rhóne-Poulenc Rorer, Antony, France); chloranbucil;GEMZAR® gemcitabine; 6-thioguanine; mercaptopurine; methotrexate;platinum coordination complexes such as cisplatin, oxaliplatin andcarboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide;mitoxantrone; vincristine; NAVELBINE® vinorelbine; novantrone;teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate;irinotecan (e.g., CPT-11); topoisomerase inhibitor RFS 2000;difluorometlhylornithine (DMFO); retinoids such as retinoic acid;capecitabine; and pharmaceutically acceptable salts, acids orderivatives of any of the above.

Also included in this definition are anti-hormonal agents that act toregulate or inhibit hormone action on tumors such as anti-estrogens andselective estrogen receptor modulators (SERMs), including, for example,tamoxifen (including NOLVADEX® tamoxifen), raloxifene, droloxifene,4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, andFARESTON toremifene; aromatase inhibitors that inhibit the enzymearomatase, which regulates estrogen production in the adrenal glands,such as, for example, 4(5)-imidazoles, aminoglutethimide, MEGASE®megestrol acetate, AROMASIN® exemestane, formestanie, fadrozole,RIVISOR® vorozole, FEMARA® letrozole, and ARIMIDEX® anastrozole; andanti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide,and goserelin; as well as troxacitabine (a 1,3-dioxolane nucleosidecytosine analog); antisense oligonucleotides, particularly those whichinhibit expression of genes in signaling pathways implicated in abherantcell proliferation, such as, for example, PKC-alpha, Ralf and H-Ras;ribozymes such as a VEGF expression inhibitor (e.g., ANGIOZYME®ribozyme) and a HER2 expression inhibitor; vaccines such as gene therapyvaccines, for example, ALLOVECTIN® vaccine, LEUVECTIN® vaccine, andVAXID® vaccine; PROLEUKIN® rIL-2; LURTOTECAN® topoisomerase 1 inhibitor;ABARELIX® rmRH; and pharmaceutically acceptable salts, acids orderivatives of any of the above.

An “intraocular neovascular disease” is a disease characterized byocular neovascularization. Examples of intraocular neovascular diseasesinclude, but are not limited to, proliferative retinopathies, choroidalneovascularization (CNV), age-related macular degeneration (AMD),diabetic and other ischemia-related retinopathies, diabetic macularedema, pathological myopia, von Hippel-Lindau disease, histoplasmosis ofthe eye, Central Retinal Vein Occlusion (CRVO), cornealneovascularization, retinal neovascularization, etc.

The “pathology” of a disease includes all phenomena that compromise thewell-being of the patient. For cancer, this includes, withoutlimitation, abnormal or uncontrollable cell growth, metastasis,interference with the normal functioning of neighboring cells, releaseof cytokines or other secretory products at abnormal levels, suppressionor aggravation of inflammatory or immunological response, etc.

Administration “in combination with” one or more further therapeuticagents includes simultaneous (concurrent) and consecutive administrationin any order.

“Carriers” as used herein include pharmaceutically acceptable carriers,excipients, or stabilizers which are nontoxic to the cell or mammalbeing exposed thereto at the dosages and concentrations employed. Oftenthe physiologically acceptable carrier is an aqueous pH bufferedsolution. Examples of physiologically acceptable carriers includebuffers such as phosphate, citrate, and other organic acids;antioxidants including ascorbic acid; low molecular weight (less thanabout 10 residues) polypeptide; proteins, such as serum albumin,gelatin, or immunoglobulins; hydrophilic polymers such aspolyvinylpyrrolidone; amino acids such as glycine, glutamine,asparagine, arginine or lysine; monosaccharides, disaccharides, andother carbohydrates including glucose, mannose, or dextrins; chelatingagents such as EDTA; sugar alcohols such as mannitol or sorbitol;salt-forming counterions such as sodium; and/or nonionic surfactantssuch as TWEEN™, polyethylene glycol (PEG), and PLURONICS™.

A “liposome” is a small vesicle composed of various types of lipids,phospholipids and/or surfactant which is useful for delivery of a drug(such as an EGFL7 polypeptide or antibody thereto) to a mammal. Thecomponents of the liposome are commonly arranged in a bilayer formation,similar to the lipid arrangement of biological membranes.

A “small molecule” is defined herein to have a molecular weight belowabout 500 Daltons.

The terms “vascular endothelial growth factor”, “VEGF”, “VEGFpolypeptide” and “VEGF protein” when used herein encompass nativesequence VEGF and VEGF variants (which are further defined herein). TheVEGF polypeptide may be isolated from a variety of sources, such as fromhuman tissue types or from another source, or prepared by recombinantand/or synthetic methods.

A “native sequence VEGF” comprises a polypeptide having the same aminoacid sequence as a VEGF derived from nature. Such native sequence VEGFcan be isolated from nature or can be produced by recombinant and/orsynthetic means. The term “native sequence VEGF” specificallyencompasses naturally-occurring truncated or secreted forms (e.g., anextracellular domain sequence), naturally-occurring variant forms (e.g.,alternatively spliced forms) and naturally-occurring allelic variants ofthe VEGF. In one embodiment of the invention, the native sequence VEGFis one of the five known isoforms, consisting of 121, 145, 165, 189, and206 amino acid residues, respectively, as described, for example in U.S.Pat. Nos. 5,332,671 and 5,240,848; in PCT Publication No. WO 98/10071;Leung et al., Science 246:1306-1309 (1989); and Keck et al., Science246:1309-1312 (1989).

“VEGF variant polypeptide” means an active VEGF polypeptide as definedbelow having at least about 80%, preferably at least about 85%, morepreferably at least about 90%, event more preferably at least about 95%,most preferably at least about 98% amino acid sequence identity with theamino acid sequence of a native sequence VEGF. Such VEGF variantpolypeptides include, for instance, VEGF polypeptides wherein one ormore amino acid residues are added, or deleted, at the N- and/orC-terminus, as well as within one or more internal domains, of thenative sequence.

The sequence identity (either amino acid or nucleic acid) for VEGF isdetermined using the same approach specifically described with regard toEGFL7. Similarly, the definitions provided for agonist and antagonistsof EGFL7, including but not limited to antibodies, will apply to VEGFagonists and antagonists.

METHODS FOR CARRYING OUT THE INVENTION

EGFL7

The EGFL7 gene encodes a secreted, ECM associated protein of ˜30 kD thatis evolutionarily conserved. The human (homo sapiens) amino acidsequence (SEQ ID NO:1) shares about 77%, 47% and 43% homology to that ofthe mouse (Mus musculus; SEQ ID NO:2), frog (Xenopus laevis; SEQ IDNO:3) and zebrafish (Danio rerio; SEQ ID NO:4), respectively. The EGFL7protein contains a signal sequence, an EMI domain at the N-terminus (EMIdomain is present in a number of extracellular matrix associatedproteins involved in regulating cell adhesion), followed by two EGF-likedomains and a leucine and valine rich C-terminal region.

Nucleic acid and polypeptide molecules are used in the presentinvention. The human, mouse, xenopus and zebrafish EGFL7 amino acidsequences are provided as SEQ ID NOs: 1-4, respectively (see FIG. 1A).The zebrafish cDNA (with partial genomic intron sequence) is provided asSEQ ID NO:5 (see FIG. 1B). The polynucleotides used in the presentinvention can be obtained using standard techniques well known to thoseskilled in the art such as, for example, hybridization screening and PCRmethodology.

Accession numbers for EGFL7 are: NM_(—)016215 (homo sapiens EGFL7/VE-statin), NM_(—)178444 (mus musculus EGFL7), AF184973 (mus musculusNotch4-like), P_AAZ37135 (mus musculus TANGO125), BC044267 (xenopuslaevis NEU1). AY542170 (danio rerio EGFL7). Egfl8 accession numbers are:NM_(—)030652 (Homo Sapiens), NM_(—)152922 (mus musculus).

Preparation and Identification of Modulators of EGFL7 Activity

The present invention also encompasses methods of screening compounds toidentify those that mimic or enhance one or more biological activity ofEGFL7 (agonists); or inhibit or reduce the effect of EGFL7(antagonists). EGFL7 agonists and antagonists are also referred to asEGFL7 modulators. Screening assays for antagonist drug candidates aredesigned to identify compounds that bind or complex with EGFL7polypeptides, or otherwise interfere with the interaction of EGFL7 withother cellular proteins.

Small Molecule Screening

Small molecules may have the ability to act as EGFL7 agonists orantagonists and thus to be therapeutically useful. Such small moleculesmay include naturally occurring small molecules, synthetic organic orinorganic compounds and peptides. However, small molecules in thepresent invention are not limited to these forms. Extensive libraries ofsmall molecules are commercially available and a wide variety of assaysare well known in the art to screen these molecules for the desiredactivity.

Candidate EGFL7 agonist or antagonist small molecules are preferablyidentified first in an assay that allows for the rapid identification ofpotential modulators of EGFL7 activity. An example of such an assay is aprotein-protein binding assay wherein the ability of the candidatemolecule to bind to an EGFL7 receptor is measured. In another example,the ability of candidate molecules to interfere with EGFL7 binding to anEGFL7 receptor is measured.

In a preferred embodiment, small molecule EGFL7 agonists are identifiedby their ability to mimic one or more of the biological activities ofEGFL7. For example, small molecules are screened for their ability toinduce proliferation of endothelial cells, to promote endothelial cellsurvival, as described in examples 2 and 3 below or to induceangiogenesis, as described in example 4 below.

In another embodiment, small molecule EGFL7 antagonists are identifiedby their ability to inhibit one or more of the biological activities ofEGFL7. Thus a candidate compound is contacted with EGFL7. The biologicalactivity of the EGFL7 is then assessed. In one embodiment the ability ofthe EGFL7 to stimulate endothelial cell proliferation is determined, forexample as described in Example 2. In another embodiment the ability ofthe EGFL7 to promote endothelial cell survival is determined, forexample as described in Example 3. A compound is identified as anantagonist where the biological activity of EGFL7 is inhibited.

Compounds identified as EGFL7 agonists or antagonists may be used in themethods of the present invention. For example, EGFL7 antagonists may beused to treat cancer.

Screening Assays for Proteins that Interact with EGFL7

Any method suitable for detecting protein-protein interactions may beemployed for identifying proteins or other molecules, including but notlimited to transmembrane or intracellular proteins, that interact withEGFL7. Among the traditional methods that may be employed areco-immunoprecipitation, crosslinking and co-purification throughgradients or chromatographic columns to identify proteins that interactwith EGFL7. For such assays, the EGFL7 component can be a full-lengthprotein, a soluble derivative thereof, a peptide corresponding to adomain of interest, or a fusion protein containing some region of EGFL7.

Methods may be employed which result in the simultaneous identificationof genes that encode proteins capable of interacting with EGFL7. Thesemethods include, for example, probing expression libraries, in a mannersimilar to the well-known technique of antibody probing of λgt11libraries, using labeled EGFL7 or a variant thereof.

A method that detects protein interactions in vivo, the two-hybridsystem, is described in detail for illustration only and not by way oflimitation. One version of this system has been described (Chien et al.,Proc. Natl. Acad. Sci. USA 88:9578-9582 (1991)) and is commerciallyavailable from Clontech (Palo Alto, Calif.).

Briefly, utilizing such a system, plasmids are constructed that encodetwo hybrid proteins: one plasmid consists of nucleotides encoding theDNA-binding domain of a transcription activator protein fused to anucleotide sequence encoding EGFL7, or a polypeptide, peptide, or fusionprotein therefrom, and the other plasmid consists of nucleotidesencoding the transcription activator protein's activation domain fusedto a cDNA encoding an unknown protein which has been recombined intothis plasmid as part of a cDNA library. The DNA-binding domain fusionplasmid and the cDNA library are transformed into a strain of the yeastSaccharomyces cerevisiae that contains a reporter gene (e.g., HBS orlacZ) whose regulatory region contains the transcription activator'sbinding site. Either hybrid protein alone cannot activate transcriptionof the reporter gene: the DNA-binding domain hybrid cannot because itdoes not provide activation function and the activation domain hybridcannot because it cannot localize to the activator's binding sites.Interaction of the two hybrid proteins reconstitutes the functionalactivator protein and results in expression of the reporter gene, whichis detected by an assay for the reporter gene product.

The two-hybrid system or related methodology may be used to screenactivation domain libraries for proteins that interact with the “bait”gene product. By way of example, and not by way of limitation, EGFL7 canbe used as the bait gene product. Total genomic or cDNA sequences arefused to the DNA encoding an activation domain. This library and aplasmid encoding a hybrid of a bait EGFL7 gene product fused to theDNA-binding domain are cotransformed into a yeast reporter strain, andthe resulting transformants are screened for those that express thereporter gene. For example, and not by way of limitation, a bait EGFL7gene sequence, e.g., the genes open reading frame, can be cloned into avector such that it is translationally fused to the DNA encoding theDNA-binding domain of the GAL4 protein. These colonies are purified andthe library plasmids responsible for reporter gene expression areisolated. DNA sequencing is then used to identify the proteins encodedby the library plasmids.

A cDNA library of the cell line from which proteins that interact withthe bait EGFL7 gene product are to be detected can be made using methodsroutinely practiced in the art. According to the particular systemdescribed herein, for example, the cDNA fragments can be inserted into avector such that they are translationally fused to the transcriptionalactivation domain of GAL4. This library can be co-transformed along withthe bait EGFL7 gene-GALA fusion plasmid into a yeast strain thatcontains a lacZ gene driven by a promoter which contains a GALAactivation sequence. A cDNA encoded protein, fused to GAL4transcriptional activation domain, that interacts with the bait EGFL7gene product will reconstitute an active GAL4 protein and thereby driveexpression. Colonies that drive expression can be detected by methodsroutine in the art. The cDNA can then be purified from these strains,and used to produce and isolate the bait EGFL7 gene-interacting proteinusing techniques routinely practiced in the art.

Assays for Compounds that Modulate EGFL7 Expression or Activity

The following assays are designed to identify compounds that interactwith (e.g., bind to) EGFL7, compounds that interfere with theinteraction of EGFL7 with its binding partners, cognate or receptor, andto compounds that modulate the activity of EGFL7 gene expression (i.e.,modulate the level of EGFL7 gene expression) or modulate the levels ofEGFL7 in the body. Assays may additionally be utilized which identifycompounds that bind to EGFL7 gene regulatory sequences (e.g., promotersequences) and, consequently, may modulate EGFL7 gene expression. See,e.g., Platt, K. A., J. Biol. Chem. 269:28558-28562 (1994), which isincorporated herein by reference in its entirety.

The compounds which may be screened in accordance with the inventioninclude, but are not limited to peptides, antibodies and fragmentsthereof, and other organic compounds (e.g., peptidomimetics) that bindto an EGFL7 or an EGFL7 receptor and either mimic the activity triggeredby a natural ligand (i.e., agonists) or inhibit the activity triggeredby the natural ligand (i.e., antagonists).

Such compounds may include, but are not limited to, peptides such as,for example, soluble peptides, including but not limited to members ofrandom peptide libraries; (see, e.g., Lam, K. S. et al., Nature354:82-84 (1991); Houghten, R. et al., Nature 354:84-86 (1991)), andcombinatorial chemistry-derived molecular library made of D- and/orL-configuration amino acids, phosphopeptides (including, but not limitedto members of random or partially degenerate, directed phosphopeptidelibraries; see, e.g., Songyang, Z. et al., Cell 72:767-778 (1993)),antibodies (including, but not limited to, polyclonal, monoclonal,humanized, anti-idiotypic, chimeric or single chain antibodies, and FAb,F(ab′)₂ and FAb expression library fragments, and epitope-bindingfragments thereof), and small organic or inorganic molecules.

Other compounds which can be screened in accordance with the inventioninclude, but are not limited to small organic molecules that are able togain entry into an appropriate cell (e.g. an endothelial cell) andaffect the expression of an EGFL7 gene or some other gene involved in anEGFL7 mediated pathway (e.g., by interacting with the regulatory regionor transcription factors involved in gene expression); or such compoundsthat affect or substitute for the activity of the EGFL7 or the activityof some other intracellular factor involved in an EGFL7 signaltransduction, catabolic, or metabolic pathways.

Computer modeling and searching technologies permit identification ofcompounds, or the improvement of already identified compounds, that canmodulate EGFL7 expression or activity. Having identified such a compoundor composition, the active sites or regions are identified. Such activesites might typically be ligand binding sites. The active site can beidentified using methods known in the art including, for example, fromthe amino acid sequences of peptides, from the nucleotide sequences ofnucleic acids, or from study of complexes of the relevant compound orcomposition with its natural ligand. In the latter case, chemical orX-ray crystallographic methods can be used to find the active site byfinding where on the factor the complexed ligand is found.

Next, the three dimensional geometric structure of the active site isdetermined. This can be done by known methods, including X-raycrystallography, which can determine a complete molecular structure. Onthe other hand, solid or liquid phase NMR can be used to determinecertain intra-molecular distances. Any other experimental method ofstructure determination can be used to obtain partial or completegeometric structures. The geometric structures may be measured with acomplexed ligand, natural or artificial, which may increase the accuracyof the active site structure determined.

If an incomplete or insufficiently accurate structure is determined, themethods of computer based numerical modeling can be used to complete thestructure or improve its accuracy. Any recognized modeling method may beused, including parameterized models specific to particular biopolymerssuch as proteins or nucleic acids, molecular dynamics models based oncomputing molecular motions, statistical mechanics models based onthermal ensembles, or combined models. For most types of models,standard molecular force fields, representing the forces betweenconstituent atoms and groups, are necessary, and can be selected fromforce fields known in physical chemistry. The incomplete or lessaccurate experimental structures can serve as constraints on thecomplete and more accurate structures computed by these modelingmethods.

Finally, having determined the structure of the active site (or bindingsite), either experimentally, by modeling, or by a combination,candidate modulating compounds can be identified by searching databasescontaining compounds along with information on their molecularstructure. Such a search seeks compounds having structures that matchthe determined active site structure and that interact with the groupsdefining the active site. Such a search can be manual, but is preferablycomputer assisted. These compounds found from this search are potentialmodulators of EGFL7 activity.

Alternatively, these methods can be used to identify improved modulatingcompounds from an already known modulating compound or ligand. Thecomposition of the known compound can be modified and the structuraleffects of modification can be determined using the experimental andcomputer modeling methods described above applied to the newcomposition. The altered structure is then compared to the active sitestructure of the compound to determine if an improved fit or interactionresults. In this manner systematic variations in composition, such as byvarying side groups, can be quickly evaluated to obtain modifiedmodulating compounds or ligands of improved specificity or activity.

Further experimental and computer modeling methods useful to identifymodulating compounds based upon identification of the active sites (orbinding sites) of EGFL7, and related transduction and transcriptionfactors will be apparent to those of skill in the art.

Examples of molecular modeling systems are the CHARMm and QUANTAprograms (Polygen Corporation, Waltham, Mass.). CHARMm performs theenergy minimization and molecular dynamics functions. QUANTA performsthe construction, graphic modeling and analysis of molecular structure.QUANTA allows interactive construction, modification, visualization, andanalysis of the behavior of molecules with each other.

A number of articles review computer modeling of drugs interactive withspecific proteins, such as Rotivinen, et al., Acta PharmaceuticalFennica 97:159-166 (1988); Ripka, New Scientist 54-57 (Jun. 16, 1988);McKinaly and Rossmann, Annu. Rev. Pharmacol. Toxiciol. 29:111-122(1989); Perry and Davies, OSAR: Quantitative Structure-ActivityRelationships in Drug Design pp. 189-193 (Alan R. Liss, Inc. 1989);Lewis and Dean, Proc. R. Soc. Lond. 236:125-140 (1989) and 141-162; and,with respect to a model receptor for nucleic acid components, Askew, etal., J. Am. Chem. Soc. 111: 1082-1090 (1989). Other computer programsthat screen and graphically depict chemicals are available fromcompanies such as BioDesign, Inc. (Pasadena, Calif.), Allelix, Inc.(Mississauga, Ontario, Canada), and Hypercube, Inc. (Cambridge,Ontario). Although these are primarily designed for application to drugsspecific to particular proteins, they can be adapted to design of drugsspecific to regions of DNA or RNA, once that region is identified.

Although described above with reference to design and generation ofcompounds which could alter binding, one could also screen libraries ofknown compounds, including natural products or synthetic chemicals, andbiologically active materials, including proteins, for compounds whichare inhibitors or activators.

Compounds identified via assays such as those described herein may beuseful, for example, in elucidating the biological function of an EGFL7gene product. Such compounds can be administered to a patient attherapeutically effective doses to treat any of a variety ofphysiological disorders. A therapeutically effective dose refers to thatamount of the compound sufficient to result in any amelioration,impediment, prevention, or alteration of any biological symptom.

Assays for Compounds that Bind to EGFL7

Systems may be designed to identify compounds capable of interactingwith (e.g., binding to) or mimicking EGFL7, or capable of interferingwith the binding of EGFL7 to a cognate receptor, binding partner orsubstrate. The compounds identified can be useful, for example, inmodulating the activity of wild type and/or mutant EGFL7 gene products;can be useful in elaborating the biological function of EGFL7; can beutilized in screens for identifying compounds that disrupt normal EGFL7interactions; or may themselves disrupt or activate such interactions.

The principle of the assays used to identify compounds that bind toEGFL7, or EGFL7 cognate receptors or substrates, involves preparing areaction mixture of EGFL7 and the test compound under conditions and fora time sufficient to allow the two components to interact and bind, thusforming a complex which can be removed and/or detected in the reactionmixture. The EGFL7 species used can vary depending upon the goal of thescreening assay. For example, where agonists of the natural receptor aredesired, the full-length EGFL7, or a soluble truncated EGFL7, a peptide,or fusion protein containing one or more EGFL7 domains fused to aprotein or polypeptide that affords advantages in the assay system(e.g., labeling, isolation of the resulting complex, etc.) can beutilized. Where compounds that directly interact with EGFL7 are sought,peptides corresponding to the EGFL7 and fusion proteins containing EGFL7can be used.

The screening assays can be conducted in a variety of ways. For example,one method to conduct such an assay would involve anchoring the EGFL7,polypeptide, peptide, or fusion protein therefrom, or the test substanceonto a solid phase and detecting EGFL7/test compound complexes anchoredon the solid phase at the end of the reaction. In one embodiment of sucha method, the EGFL7 reactant may be anchored onto a solid surface, andthe test compound, which is not anchored, may be labeled, eitherdirectly or indirectly.

In practice, microtiter plates may conveniently be utilized as the solidphase. The anchored component may be immobilized by non-covalent orcovalent attachments. Non-covalent attachment may be accomplished bysimply coating the solid surface with a solution of the protein anddrying. Alternatively, an immobilized antibody, preferably a monoclonalantibody, specific for the protein to be immobilized may be used toanchor the protein to the solid surface. The surfaces may be prepared inadvance and stored.

In order to conduct the assay, the nonimmobilized component is added tothe coated surface containing the anchored component. After the reactionis complete, unreacted components are removed (e.g., by washing) underconditions such that any complexes formed will remain immobilized on thesolid surface. The detection of complexes anchored on the solid surfacecan be accomplished in a number of ways. Where the previouslynonimmobilized component is pre-labeled, the detection of labelimmobilized on the surface indicates that complexes were formed. Wherethe previously nonimmobilized component is not pre-labeled, an indirectlabel can be used to detect complexes anchored on the surface; e.g.,using a labeled antibody specific for the previously nonimmobilizedcomponent (the antibody, in turn, may be directly labeled or indirectlylabeled with a labeled anti-Ig antibody).

Alternatively, a reaction can be conducted in a liquid phase, thereaction products separated from unreacted components, and complexesdetected; e.g., using an immobilized antibody specific for an EGFL7protein, polypeptide, peptide or fusion protein or the test compound toanchor any complexes formed in solution, and a labeled antibody specificfor the other component of the possible complex to detect anchoredcomplexes.

Assays for Compounds that Interfere with EGFL7 Interactions

Macromolecules that interact with EGFL7 are referred to, for purposes ofthis discussion, as “binding partners”. These binding partners arelikely to be involved in EGFL7 mediated biological pathways. Therefore,it is desirable to identify compounds that interfere with or disrupt theinteraction of such binding partners which may be useful in regulatingor augmenting EGFL7 activity in the body and/or controlling disordersassociated with this activity (or a deficiency thereof).

The basic principle of the assay systems used to identify compounds thatinterfere with the interaction between EGFL7 and a binding partner orpartners involves preparing a reaction mixture containing EGFL7, or somevariant thereof, and the binding partner under conditions and for a timesufficient to allow the two to interact and bind, thus forming acomplex. In order to test a compound for inhibitory activity, thereaction mixture is prepared in the presence and absence of the testcompound. The test compound may be initially included in the reactionmixture, or may be added at a time subsequent to the addition of theEGFL7 and its binding partner. Control reaction mixtures are incubatedwithout the test compound or with a placebo. The formation of anycomplexes between the EGFL7 and the binding partner is then detected.The formation of a complex in the control reaction, but not in thereaction mixture containing the test compound, indicates that thecompound interferes with the interaction of the EGFL7 and theinteractive binding partner. Additionally, complex formation withinreaction mixtures containing the test compound and normal EGFL7 proteinmay also be compared to complex formation within reaction mixturescontaining the test compound and a mutant EGFL7. This comparison may beimportant in those cases wherein it is desirable to identify compoundsthat specifically disrupt interactions of mutant, or mutated, EGFL7 butnot the normal proteins. The assay for compounds that interfere with theinteraction between EGFL7 and binding partners can be conducted in aheterogeneous or homogeneous format. Heterogeneous assays involveanchoring either the EGFL7, or the binding partner, onto a solid phaseand detecting complexes anchored on the solid phase at the end of thereaction. In homogeneous assays, the entire reaction is carried out in aliquid phase. In either approach, the order of addition of reactants canbe varied to obtain different information about the compounds beingtested. For example, test compounds that interfere with the interactionby competition can be identified by conducting the reaction in thepresence of the test substance; i.e., by adding the test substance tothe reaction mixture prior to, or simultaneously with, EGFL7 andinteractive binding partner. Alternatively, test compounds that disruptpreformed complexes, e.g. compounds with higher binding constants thatdisplace one of the components from the complex, can be tested by addingthe test compound to the reaction mixture after complexes have beenformed. The various formats are described briefly below.

In a heterogeneous assay system, either EGFL7 or an interactive bindingpartner, is anchored onto a solid surface, while the non-anchoredspecies is labeled, either directly or indirectly. In practice,microtiter plates are conveniently utilized. The anchored species may beimmobilized by non-covalent or covalent attachments. Non-covalentattachment may be accomplished simply by coating the solid surface witha solution of the EGFL7 or binding partner and drying. Alternatively, animmobilized antibody specific for the species to be anchored may be usedto anchor the species to the solid surface. The surfaces may be preparedin advance and stored.

In order to conduct the assay, the partner of the immobilized species isexposed to the coated surface with or without the test compound. Afterthe reaction is complete, unreacted components are removed (e.g., bywashing) and any complexes formed will remain immobilized on the solidsurface. The detection of complexes anchored on the solid surface can beaccomplished in a number of ways. Where the non-immobilized species ispre-labeled, the detection of label immobilized on the surface indicatesthat complexes were formed. Where the non-immobilized species is notpre-labeled, an indirect label can be used to detect complexes anchoredon the surface; e.g., using a labeled antibody specific for theinitially non-immobilized species (the antibody, in turn, may bedirectly labeled or indirectly labeled with a labeled anti-Ig antibody).Depending upon the order of addition of reaction components, testcompounds which inhibit complex formation or which disrupt preformedcomplexes can be detected.

Alternatively, the reaction can be conducted in a liquid phase in thepresence or absence of the test compound, the reaction productsseparated from unreacted components, and complexes detected; e.g., usingan immobilized antibody specific for one of the binding components toanchor any complexes formed in solution, and a labeled antibody specificfor the other partner to detect anchored complexes. Again, dependingupon the order of addition of reactants to the liquid phase, testcompounds which inhibit complex or which disrupt preformed complexes canbe identified.

In an alternate embodiment of the invention, a homogeneous assay can beused. In this approach, a preformed complex of EGFL7 and an interactivebinding partner is prepared in which either the EGFL7 or its bindingpartners is labeled, but the signal generated by the label is quencheddue to formation of the complex (see, e.g., U.S. Pat. No. 4,109,496 byRubenstein which utilizes this approach for immunoassays). The additionof a test substance that competes with and displaces one of the speciesfrom the preformed complex will result in the generation of a signalabove background. In this way, test substances that disrupt theinteraction can be identified.

In a particular embodiment, an EGFL7 fusion can be prepared forimmobilization. For example, EGFL7, or a peptide fragment thereof, canbe fused to a glutathione-S-transferase (GST) gene using a fusionvector, such as pGEX-5X-1, in such a manner that its binding activity ismaintained in the resulting fusion protein. The interactive bindingpartner can be purified and used to raise a monoclonal antibody, usingmethods routinely practiced in the art and described above. Thisantibody can be labeled with the radioactive isotope ¹²⁵I, for example,by methods routinely practiced in the art. In a heterogeneous assay, thefusion protein can be anchored to glutathione-agarose beads. Theinteractive binding partner can then be added in the presence or absenceof the test compound in a manner that allows interaction and binding tooccur. At the end of the reaction period, unbound material can be washedaway, and the labeled monoclonal antibody can be added to the system andallowed to bind to the complexed components. The interaction betweenEGFL7 and the interactive binding partner can be detected by measuringthe amount of radioactivity that remains associated with theglutathione-agarose beads. A successful inhibition of the interaction bythe test compound will result in a decrease in measured radioactivity.

Alternatively, the GST fusion protein and the interactive bindingpartner can be mixed together in liquid in the absence of the solidglutathione-agarose beads. The test compound can be added either duringor after the species are allowed to interact. This mixture can then beadded to the glutathione-agarose beads and unbound material is washedaway. Again the extent of inhibition of the interaction between EGFL7and the binding partner can be detected by adding the labeled antibodyand measuring the radioactivity associated with the beads.

In another embodiment of the invention, these same techniques can beemployed using peptide fragments that correspond to the binding domainsof EGFL7 and/or the interactive or binding partner (in cases where thebinding partner is a protein), in place of one or both of the fulllength proteins. Any number of methods routinely practiced in the artcan be used to identify and isolate the binding sites. These methodsinclude, but are not limited to, mutagenesis of the gene encoding one ofthe proteins and screening for disruption of binding in aco-immunoprecipitation assay. Compensatory mutations in the geneencoding the second species in the complex can then be selected.Sequence analysis of the genes encoding the respective proteins willreveal the mutations that correspond to the region of the proteininvolved in interactive binding. Alternatively, one protein can beanchored to a solid surface using methods described above, and allowedto interact with and bind to its labeled binding partner, which has beentreated with a proteolytic enzyme, such as trypsin. After washing, arelatively short, labeled peptide comprising the binding domain mayremain associated with the solid material, which can be isolated andidentified by amino acid sequencing. Also, once the gene coding for theintracellular binding partner is obtained, short gene segments can beengineered to express peptide fragments of the protein, which can thenbe tested for binding activity and purified or synthesized.

For example, and not by way of limitation, EGFL7 can be anchored to asolid material as described, above, by making a GST fusion protein andallowing it to bind to glutathione agarose beads. The interactivebinding partner can be labeled with a radioactive isotope, such as ³⁵S,and cleaved with a proteolytic enzyme such as trypsin. Cleavage productscan then be added to the anchored fusion protein and allowed to bind.After washing away unbound peptides, labeled bound material,representing the intracellular binding partner binding domain, can beeluted, purified, and analyzed for amino acid sequence by well-knownmethods. Peptides so identified can be produced synthetically or fusedto appropriate facilitative proteins using recombinant DNA technology.

Uses of EGFL7 Compositions

Assays for Cardiovascular, Endothelial, and Angiogenic Activity

Various assays can be used to test the polypeptide herein forcardiovascular, endothelial, and angiogenic activity. Such assaysinclude those provided in the Examples below.

Assays for tissue generation activity include, without limitation, thosedescribed in WO 95/16035 (bone, cartilage, tendon); WO 95/05846 (nerve,neuronal), and WO 91/07491 (skin, endothelium).

Assays for wound-healing activity include, for example, those describedin Winter, Epidermal Wound Healing, Maibach, H I and Rovee, D T, eds.(Year Book Medical Publishers, Inc., Chicago), pp. 71-112, as modifiedby the article of Eaglstein and Mertz, J. Invest. Dermatol. 71:382-384(1978).

There are several cardiac hypertrophy assays. In vitro assays includeinduction of spreading of adult rat cardiac myocytes. In this assay,ventricular myocytes are isolated from a single (male Sprague-Dawley)rat, essentially following a modification of the procedure described indetail by Piper et al., “Adult ventricular rat heart muscle cells” inCell Culture Techniques in Heart and Vessel Research, H. M. Piper, ed.(Berlin: Springer-Verlag, 1990), pp. 36-60. This procedure permits theisolation of adult ventricular myocytes and the long-term culture ofthese cells in the rod-shaped phenotype. Phenylephrine and ProstaglandinF_(2α) (PGF_(2α)) have been shown to induce a spreading response inthese adult cells. The inhibition of myocyte spreading induced byPGF_(2α) or PGF_(2α) analogs (e.g., fluprostenol) and phenylephrine byvarious potential inhibitors of cardiac hypertrophy is then tested.

For cancer, a variety of well-known animal models can be used to furtherunderstand the role of EGFL7 in the development and pathogenesis oftumors, and to test the efficacy of candidate therapeutic agents,including antibodies and other antagonists of native EGFL7 polypeptides,such as small-molecule antagonists. The in vivo nature of such modelsmakes them particularly predictive of responses in human patients.Animal models of tumors and cancers (e.g., breast cancer, colon cancer,prostate cancer, lung cancer, etc.) include both non-recombinant andrecombinant (transgenic) animals. Non-recombinant animal models include,for example, rodent, e.g., murine models. Such models can be generatedby introducing tumor cells into syngeneic mice using standardtechniques, e.g., subcutaneous injection, tail vein injection, spleenimplantation, intraperitoneal implantation, implantation under the renalcapsule, or orthopin implantation, e.g., colon cancer cells implanted incolonic tissue. See, e.g., PCT publication No. WO 97/33551, publishedSep. 18, 1997. Probably the most often used animal species inoncological studies are immunodeficient mice and, in particular, nudemice. The observation that the nude mouse with thymic hypo/aplasia couldsuccessfully act as a host for human tumor xenografts has lead to itswidespread use for this purpose. The autosomal recessive nu gene hasbeen introduced into a very large number of distinct congenic strains ofnude mouse, including, for example, ASW, A/He, AKR, BALB/c, B10.LP, C17,C3H, C57BL, C57, CBA, DBA, DDD, I/st, NC, NFR, NFS, NFS/N, NZB, NZC,NZW, P, RIII, and SJL. In addition, a wide variety of other animals withinherited immunological defects other than the nude mouse have been bredand used as recipients of tumor xenografts. For further details see,e.g., The Nude Mouse in Oncology Research, E. Boven and B. Winograd,eds. (CRC Press, Inc., 1991).

The cells introduced into such animals can be derived from knowntumor/cancer cell lines, such as any of the above-listed tumor celllines, and, for example, the B 104-1-1 cell line (stable NIH-3T3 cellline transfected with the neu protooncogene); ras-transfected NIH-3T3cells; Caco-2 (ATCC HTB-37); or a moderately well-differentiated gradeII human colon adenocarcinoma cell line, HT-29 (ATCC HTB-38); or fromtumors and cancers. Samples of tumor or cancer cells can be obtainedfrom patients undergoing surgery, using standard conditions involvingfreezing and storing in liquid nitrogen. Karmali et al., Br. J. Cancer48:689-696 (1983).

Tumor cells can be introduced into animals, such as nude mice or EGFL7knockout mice, by a variety of procedures. The subcutaneous (s.c.) spacein mice is very suitable for tumor implantation. Tumors can betransplanted s.c. as solid blocks, as needle biopsies by use of atrochar, or as cell suspensions. For solid-block or trocharimplantation, tumor tissue fragments of suitable size are introducedinto the s.c. space. Cell suspensions are freshly prepared from primarytumors or stable tumor cell lines, and injected subcutaneously. Tumorcells can also be injected as subdermal implants. In this location, theinoculum is deposited between the lower part of the dermal connectivetissue and the s.c. tissue.

Animal models of breast cancer can be generated, for example, byimplanting rat neuroblastoma cells (from which the neu oncogene wasinitially isolated), or neu-transformed NIH-3T3 cells into nude mice,essentially as described by Drebin et al. Proc. Nat. Acad. Sci. USA83:9129-9133 (1986).

Similarly, animal models of colon cancer can be generated by passagingcolon cancer cells in animals, e.g., nude mice, leading to theappearance of tumors in these animals. An orthotopic transplant model ofhuman colon cancer in nude mice has been described, for example, by Wanget al., Cancer Research 54:4726-4728 (1994) and Too et al., CancerResearch 55:681-684 (1995). This model is based on the so-called“METAMOUSE™” sold by AntiCancer, Inc., (San Diego, Calif.).

Tumors that arise in animals can be removed and cultured in vitro. Cellsfrom the in vitro cultures can then be passage to animals. Such tumorscan serve as targets for further testing or drug screening.Alternatively, the tumors resulting from the passage can be isolated andRNA from pre-passage cells and cells isolated after one or more roundsof passage analyzed for differential expression of genes of interest.Such passaging techniques can be performed with any known tumor orcancer cell lines.

For example, Meth A, CMS4, CMS5, CMS21, and WEHI-164 are chemicallyinduced fibrosarcomas of BALB/c female mice (DeLeo et al., J. Exp. Med.146:720 (1977)), which provide a highly controllable model system forstudying the anti-tumor activities of various agents. Palladino et al.,J. Immunol. 138:4023-4032 (1987). Briefly, tumor cells are propagated invitro in cell culture. Prior to injection into the animals, the celllines are washed and suspended in buffer, at a cell density of about10×10⁶ to 10×10⁷ cells/ml. The animals are then infected subcutaneouslywith 10 to 100 μl of the cell suspension, allowing one to three weeksfor a tumor to appear.

In addition, the Lewis lung carcinoma of mice, which is one of the mostthoroughly studied experimental tumors, can be used as aninvestigational tumor model. Efficacy in this tumor model has beencorrelated with beneficial effects in the treatment of human patientsdiagnosed with small-cell carcinoma of the lung (SCCL). This tumor canbe introduced in normal mice upon injection of tumor fragments from anaffected mouse or of cells maintained in culture. Zupi et al., Br. J.Cancer 41: suppl. 4, 30 (1980). Evidence indicates that tumors can bestarted from injection of even a single cell and that a very highproportion of infected tumor cells survive. For further informationabout this tumor model see, Zacharski, Haemostasis 16:300-320 (1986).

One way of evaluating the efficacy of a test compound in an animal modelwith an implanted tumor is to measure the size of the tumor before andafter treatment. Traditionally, the size of implanted tumors has beenmeasured with a slide caliper in two or three dimensions. The measurelimited to two dimensions does not accurately reflect the size of thetumor; therefore, it is usually converted into the corresponding volumeby using a mathematical formula. However, the measurement of tumor sizeis very inaccurate. The therapeutic effects of a drug candidate can bebetter described as treatment-induced growth delay and specific growthdelay. Another important variable in the description of tumor growth isthe tumor volume doubling time. Computer programs for the calculationand description of tumor growth are also available, such as the programreported by Rygaard and Spang-Thomsen, Proc. 6th Int. Workshop onImmune-Deficient Animals, Wu and Sheng eds. (Basel, 1989), p. 301. It isnoted, however, that necrosis and inflammatory responses followingtreatment may actually result in an increase in tumor size, at leastinitially. Therefore, these changes need to be carefully monitored, by acombination of a morphometric method and flow cytometric analysis.

Further, recombinant (transgenic) animal models can be engineered byintroducing the coding portion of the EGFL7 gene identified herein intothe genome of animals of interest, using standard techniques forproducing transgenic animals. Animals that can serve as a target fortransgenic manipulation include, without limitation, mice, rats,rabbits, guinea pigs, sheep, goats, pigs, and non-human primates, e.g.,baboons, chimpanzees and monkeys. Techniques known in the art tointroduce a transgene into such animals include pronucleicmicroinjection (U.S. Pat. No. 4,873,191); retrovirus-mediated genetransfer into germ lines (e.g., Van der Putten et al., Proc. Natl. Acad.Sci. USA 82:6148-615 (1985)); gene targeting in embryonic stem cells(Thompson et al., Cell 56:313-321 (1989)); electroporation of embryos(Lo, Mol. Cell. Biol. 3:1803-1814 (1983)); and sperm-mediated genetransfer. Lavitrano et al., Cell 57:717-73 (1989). For a review, see forexample, U.S. Pat. No. 4,736,866.

For the purpose of the present invention, transgenic animals includethose that carry the transgene only in part of their cells (“mosaicanimals”). The transgene can be integrated either as a single transgene,or in concatamers, e.g., head-to-head or head-to-tail tandems. Selectiveintroduction of a transgene into a particular cell type is also possibleby following, for example, the technique of Lasko et al., Proc. Natl.Acad. Sci. USA 89:6232-636 (1992). The expression of the transgene intransgenic animals can be monitored by standard techniques. For example,Southern blot analysis or PCR amplification can be used to verify theintegration of the transgene. The level of MRNA expression can then beanalyzed using techniques such as in situ hybridization, Northern blotanalysis, PCR, or immunocytochemistry. The animals are further examinedfor signs of tumor or cancer development.

Alternatively, “knock-out” animals can be constructed that have adefective or altered gene encoding EGFL7 identified herein, as a resultof homologous recombination between the endogenous gene encoding EGFL7and altered genomic DNA encoding the same polypeptide introduced into anembryonic cell of the animal. For example, cDNA encoding a particularEGFL7 polypeptide can be used to clone genomic DNA encoding thatpolypeptide in accordance with established techniques. A portion of thegenomic DNA encoding a particular EGFL7 polypeptide can be deleted orreplaced with another gene, such as a gene encoding a selectable markerthat can be used to monitor integration. Typically, several kilobases ofunaltered flanking DNA (both at the 5′ and 3′ ends) are included in thevector. See, e.g., Thomas and Capecchi, Cell 51:503 (1987) for adescription of homologous recombination vectors. The vector isintroduced into an embryonic stem cell line (e.g., by electroporation)and cells in which the introduced DNA has homologously recombined withthe endogenous DNA are selected. See, e.g., Li et al., Cell 69:915(1992). The selected cells are then injected into a blastocyst of ananimal (e.g., a mouse or rat) to form aggregation chimeras. See, e.g.,Bradley, in Teratocarcinomas and Embryonic Stem Cells: A PracticalApproach, E. J. Robertson, ed. (IRL: Oxford, 1987), pp. 113-152. Achimeric embryo can then be implanted into a suitable pseudopregnantfemale foster animal and the embryo brought to term to create a“knock-out” animal. Progeny harboring the homologously recombined DNA intheir germ cells can be identified by standard techniques and used tobreed animals in which all cells of the animal contain the homologouslyrecombined DNA. Knockout animals can be characterized, for instance, bytheir ability to defend against certain pathological conditions and bytheir development of pathological conditions due to absence of EGFL7.

The efficacy of antibodies specifically binding EGFL7 identified herein,and other drug candidates, can be tested also in the treatment ofspontaneous animal tumors. A suitable target for such studies is thefeline oral squamous cell carcinoma (SCC). Feline oral SCC is a highlyinvasive, malignant tumor that is the most common oral malignancy ofcats, accounting for over 60% of the oral tumors reported in thisspecies. It rarely metastasizes to distant sites, although this lowincidence of metastasis may merely be a reflection of the short survivaltimes for cats with this tumor. These tumors are usually not amenable tosurgery, primarily because of the anatomy of the feline oral cavity. Atpresent, there is no effective treatment for this tumor. Prior to entryinto the study, each cat undergoes complete clinical examination andbiopsy, and is scanned by computed tomography (CT). Cats diagnosed withsublingual oral squamous cell tumors are excluded from the study. Thetongue can become paralyzed as a result of such tumor, and even if thetreatment kills the tumors the animals may not be able to feedthemselves. Each cat is treated repeatedly, over a longer period oftime. Photographs of the tumors will be taken daily during the treatmentperiod, and at each subsequent recheck. After treatment, each catundergoes another CT scan. CT scans and thoracic radiograms areevaluated every 8 weeks thereafter. The data are evaluated fordifferences in survival, response, and toxicity as compared to controlgroups. Positive response may require evidence of tumor regression,preferably with improvement of quality of life and/or increased lifespan.

In addition, other spontaneous animal tumors, such as fibrosarcoma,adenocarcinoma, lymphoma, chondroma, or leiomyosarcoma of dogs, cats,and baboons can also be tested. Of these, mammary adenocarcinoma in dogsand cats is a preferred model as its appearance and behavior are verysimilar to those in humans. However, the use of this model is limited bythe rare occurrence of this type of tumor in animals.

Other in vitro and in vivo cardiovascular, endothelial, and angiogenictests known in the art are also suitable herein.

Tissue Distribution

The results of the cardiovascular, endothelial, and angiogenic assaysherein can be verified by further studies, such as by determining mRNAexpression in various human tissues.

As noted before, gene amplification and/or gene expression in varioustissues may be measured by conventional Southern blotting, Northernblotting to quantitate the transcription of mRNA (Thomas, Proc. Nat.Acad. Sci. USA 77:5201-5205 (1980)), dot blotting (DNA analysis), or insitu hybridization, using an appropriately labeled probe, based on thesequences provided herein. Alternatively, antibodies may be employedthat can recognize specific duplexes, including DNA duplexes, RNAduplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes.

Gene expression in various tissues, alternatively, may be measured byimmunological methods, such as immunohistochemical staining of tissuesections and assay of cell culture or body fluids, to quantitatedirectly the expression of gene product. Antibodies useful forimmunohistochemical staining and/or assay of sample fluids may be eithermonoclonal or polyclonal, and may be prepared in any mammal.Conveniently, the antibodies may be prepared against a native-sequenceEGFL7 polypeptide or against a synthetic peptide based on the DNAsequences provided herein or against exogenous sequence fused to EGFL7DNA and encoding a specific antibody epitope. General techniques forgenerating antibodies, and special protocols for in situ hybridizationare provided herein below.

Antibody Binding Studies

The results of the cardiovascular, endothelial, and angiogenic study canbe further verified by antibody binding studies, in which the ability ofanti-EGFL7 antibodies to inhibit the effect of EGFL7s on endothelialcells or other cells used in the cardiovascular, endothelial, andangiogenic assays is tested. Exemplary antibodies include polyclonal,monoclonal, humanized, bispecific, and heteroconjugate antibodies, thepreparation of which will be described hereinbelow.

Antibody binding studies may be carried out in any known assay method,such as competitive binding assays, direct and indirect sandwich assays,and immunoprecipitation assays. Zola, Monoclonal Antibodies: A Manual ofTechniques (CRC Press, Inc., 1987), pp. 147-158.

Competitive binding assays rely on the ability of a labeled standard tocompete with the test sample analyte for binding with a limited amountof antibody. The amount of target protein in the test sample isinversely proportional to the amount of standard that becomes bound tothe antibodies. To facilitate determining the amount of standard thatbecomes bound, the antibodies preferably are insolubilized before orafter the competition, so that the standard and analyte that are boundto the antibodies may conveniently be separated from the standard andanalyte that remain unbound.

Sandwich assays involve the use of two antibodies, each capable ofbinding to a different immunogenic portion, or epitope, of the proteinto be detected. In a sandwich assay, the test sample analyte is bound bya first antibody that is immobilized on a solid support, and thereaftera second antibody binds to the analyte, thus forming an insolublethree-part complex. See, e.g., U.S. Pat. No. 4,376,110. The secondantibody may itself be labeled with a detectable moiety (direct sandwichassays) or may be measured using an anti-immunoglobulin antibody that islabeled with a detectable moiety (indirect sandwich assay). For example,one type of sandwich assay is an ELISA assay, in which case thedetectable moiety is an enzyme.

For imnunohistochemistry, the tissue sample may be fresh or frozen ormay be embedded in paraffin and fixed with a preservative such asformalin, for example.

Cell-Based Tumor Assays

Cell-based assays and animal models for cardiovascular, endothelial, andangiogenic disorders, such as tumors, can be used to verify the findingsof a cardiovascular, endothelial, and angiogenic assay herein, andfurther to understand the relationship between the gene identifiedherein and the development and pathogenesis of undesirablecardiovascular, endothelial, and angiogenic cell growth. The role ofgene products identified herein in the development and pathology ofundesirable cardiovascular, endothelial, and angiogenic cell growth,e.g., tumor cells, can be tested by using cells or cells lines that havebeen identified as being stimulated or inhibited by EGFL7 herein. Suchcells include, for example, those set forth in the Examples below.

In a different approach, cells of a cell type known to be involved in aparticular cardiovascular, endothelial, and angiogenic disorder aretransfected with the cDNAs herein, and the ability of these cDNAs toinduce excessive growth or inhibit growth is analyzed. If thecardiovascular, endothelial, and angiogenic disorder is cancer, suitabletumor cells include, for example, stable tumor cell lines such as theB104-1-1 cell line (stable NIH-3T3 cell line transfected with the neuprotooncogene) and ras-transfected NIH-3T3 cells, which can betransfected with the desired gene and monitored for tumorigenic growth.Such transfected cell lines can then be used to test the ability ofpoly- or monoclonal antibodies or antibody compositions to inhibittumorigenic cell growth by exerting cytostatic or cytotoxic activity onthe growth of the transformed cells, or by mediating antibody-dependentcellular cytotoxicity (ADCC). Cells transfected with the codingsequences of the gene identified herein can further be used to identifydrug candidates for the treatment of cardiovascular, endothelial, andangiogenic disorders such as cancer.

In addition, primary cultures derived from tumors in transgenic animals(as described above) can be used in the cell-based assays herein,although stable cell lines are preferred. Techniques to derivecontinuous cell lines from transgenic animals are well known in the art.See, e.g., Small et al., Mol. Cell. Biol. 5:642-648 (1985).

Use of Gene as a Diagnostic

This invention is also related to the use of the gene encoding EGFL7 asa diagnostic. Detection of a mutated form of EGFL7 will allow adiagnosis of a cardiovascular, endothelial, and angiogenic disease or asusceptibility to a cardiovascular, endothelial, and angiogenic disease,such as a tumor.

Individuals carrying mutations in the gene encoding a human EGFL7polypeptide may be detected at the DNA level by a variety of techniques.Nucleic acids for diagnosis may be obtained from a patient's cells, suchas from blood, urine, saliva, tissue biopsy, and autopsy material. Thegenomic DNA may be used directly for detection or may be amplifiedenzymatically by using PCR (Saiki et al., Nature 324:163-166 (1986))prior to analysis. RNA or cDNA may also be used for the same purpose. Asan example, PCR primers complementary to the nucleic acid encoding EGFL7can be used to identify and analyze EGFL7 mutations. For example,deletions and insertions can be detected by a change in size of theamplified product in comparison to the normal genotype. Point mutationscan be identified by hybridizing amplified DNA to radiolabeled RNAencoding EGFL7, or alternatively, radiolabeled antisense DNA sequencesencoding EGFL7. Perfectly matched sequences can be distinguished frommismatched duplexes by RNase A digestion or by differences in meltingtemperatures.

Genetic testing based on DNA sequence differences may be achieved bydetection of alteration in electrophoretic mobility of DNA fragments ingels with or without denaturing agents. Small sequence deletions andinsertions can be visualized by high resolution gel electrophoresis. DNAfragments of different sequences may be distinguished on denaturingformamidine gradient gels in which the mobilities of different DNAfragments are retarded in the gel at different positions according totheir specific melting or partial melting temperatures. See, e.g., Myerset al., Science 230:1242 (1985).

Sequence changes at specific locations may also be revealed by nucleaseprotection assays, such as RNase and S1 protection or the chemicalcleavage method, for example, Cotton et al., Proc. Natl. Acad. Sci. USA85:4397-4401 (1985).

Thus, the detection of a specific DNA sequence may be achieved bymethods such as hybridization, RNase protection, chemical cleavage,direct DNA sequencing, or the use of restriction enzymes, e.g.,restriction fragment length polymorphisms (RFLP), and Southern blottingof genomic DNA.

Use to Detect Polypeptide Expression Levels

In addition to more conventional gel-electrophoresis and DNA sequencing,mutations can also be detected by in situ analysis.

Expression of nucleic acid encoding EGFL7 may be linked to vasculardisease or neovascularization associated with tumor formation. If EGFL7has a signal sequence and the mRNA is highly expressed in endothelialcells and to a lesser extent in smooth muscle cells, this indicates thatEGFL7 is present in serum. Accordingly, an anti-EGFL7 polypeptideantibody could be used to diagnose vascular disease orneovascularization associated with tumor formation, since an alteredlevel of this EGFL7 polypeptide may be indicative of such disorders.

A competition assay may be employed wherein antibodies specific to EGFL7are attached to a solid support and the labeled EGFL7 polypeptide and asample derived from the host are passed over the solid support and theamount of label detected attached to the solid support can be correlatedto a quantity of EGFL7 in the sample.

Chromosome Mapping

The sequences of the present invention are also valuable for chromosomeidentification. The sequence is specifically targeted to and canhybridize with a particular location on an individual human chromosome.Moreover, there is a current need for identifying particular sites onthe chromosome. Few chromosome marking reagents based on actual sequencedata (repeat polymorphisms) are presently available for markingchromosomal location. The mapping of DNAs to chromosomes according tothe present invention is an important first step in correlating thosesequences with genes associated with disease.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers(preferably 15-25 bp) from the cDNA. Computer analysis for the3′-untranslated region is used to rapidly select primers that do notspan more than one exon in the genomic DNA, thus complicating theamplification process. These primers are then used for PCR screening ofsomatic cell hybrids containing individual human chromosomes. Only thosehybrids containing the human gene corresponding to the primer will yieldan amplified fragment.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning aparticular DNA to a particular chromosome. Using the present inventionwith the same oligonucleotide primers, sublocalization can be achievedwith panels of fragments from specific chromosomes or pools of largegenomic clones in an analogous manner. Other mapping strategies that cansimilarly be used to map to its chromosome include in situhybridization, prescreening with labeled flow-sorted chromosomes, andpreselection by hybridization to construct chromosome-specific cDNAlibraries.

Fluorescence in situ hybridization (FISH) of a cDNA clone to a metaphasechromosomal spread can be used to provide a precise chromosomal locationin one step. This technique can be used with cDNA as short as 500 or 600bases; however, clones larger than 2,000 bp have a higher likelihood ofbinding to a unique chromosomal location with sufficient signalintensity for simple detection. FISH requires use of the clones fromwhich the gene encoding EGFL7 was derived, and the longer the better.For example, 2,000 bp is good, 4,000 bp is better, and more than 4,000is probably not necessary to get good results a reasonable percentage ofthe time. For a review of this technique, see, Verma et al., HumanChromosomes: a Manual of Basic Techniques (Pergamon Press, New York,1988).

Once a sequence has been mapped to a precise chromosomal location, thephysical position of the sequence on the chromosome can be correlatedwith genetic map data. Such data are found, for example, in V. McKusick,Mendelian Inheritance in Man (available online through Johns HopkinsUniversity Welch Medical Library). The relationship between genes anddiseases that have been mapped to the same chromosomal region is thenidentified through linkage analysis (coinheritance of physicallyadjacent genes).

Next, it is necessary to determine the differences in the cDNA orgenomic sequence between affected and unaffected individuals. If amutation is observed in some or all of the affected individuals but notin any normal individuals, then the mutation is likely to be thecausative agent of the disease.

With current resolution of physical mapping and genetic mappingtechniques, a cDNA precisely localized to a chromosomal regionassociated with the disease could be one of between 50 and 500 potentialcausative genes. (This assumes 1 megabase mapping resolution and onegene per 20 kb).

Screening Assays for Drug Candidates

This invention encompasses methods of screening compounds to identifythose that mimic EGFL7 (agonists) or prevent the effect of EGFL7(antagonists). Screening assays for antagonist drug candidates aredesigned to identify compounds that bind or complex with EGFL7, orotherwise interfere with the interaction of the encoded polypeptideswith other cellular proteins. Such screening assays will include assaysamenable to high-throughput screening of chemical libraries, making themparticularly suitable for identifying small molecule drug candidates.

The assays can be performed in a variety of formats, includingprotein-protein binding assays, biochemical screening assays,immunoassays, and cell-based assays, which are well characterized in theart.

All assays for antagonists are common in that they call for contactingthe drug candidate with EGFL7 under conditions and for a time sufficientto allow these two components to interact.

In binding assays, the interaction is binding and the complex formed canbe isolated or detected in the reaction mixture. In a particularembodiment, EGFL7 or the drug candidate is immobilized on a solid phase,e.g., on a microtiter plate, by covalent or non-covalent attachments.Non-covalent attachment generally is accomplished by coating the solidsurface with a solution of EGFL7 and drying. Alternatively, animmobilized antibody, e.g., a monoclonal antibody, specific for EGFL7 tobe immobilized can be used to anchor it to a solid surface. The assay isperformed by adding the non-immobilized component, which may be labeledby a detectable label, to the immobilized component, e.g., the coatedsurface containing the anchored component. When the reaction iscomplete, the non-reacted components are removed, e.g., by washing, andcomplexes anchored on the solid surface are detected. When theoriginally non-immobilized component carries a detectable label, thedetection of label immobilized on the surface indicates that complexingoccurred. Where the originally non-immobilized component does not carrya label, complexing can be detected, for example, by using a labeledantibody specifically binding the immobilized complex.

If the candidate compound interacts with but does not bind to aparticular EGFL7 polypeptide, its interaction with that polypeptide canbe assayed by methods well known for detecting protein-proteininteractions. Such assays include traditional approaches, such as, e.g.,cross-linking, co-immunoprecipitation, and co-purification throughgradients or chromatographic columns. In addition, protein-proteininteractions can be monitored by using a yeast-based genetic systemdescribed by Fields and co-workers (Fields and Song, Nature (London)340:245-246 (1989); Chien et al., Proc. Natl. Acad. Sci. USA88:9578-9582 (1991)) as disclosed by Chevray and Nathans, Proc. Natl.Acad. Sci. USA 89:5789-5793 (1991). Many transcriptional activators,such as yeast GAL4, consist of two physically discrete modular domains,one acting as the DNA-binding domain, the other one functioning as thetranscription-activation domain. The yeast expression system describedin the foregoing publications (generally referred to as the “two-hybridsystem”) takes advantage of this property, and employs two hybridproteins, one in which the target protein is fused to the DNA-bindingdomain of GAL4, and another, in which candidate activating proteins arefused to the activation domain. The expression of a GAL1-lacZ reportergene under control of a GAL4-activated promoter depends onreconstitution of GALA activity via protein-protein interaction.Colonies containing interacting polypeptides are detected with achromogenic substrate for β-galactosidase. A complete kit (MATCHMAKER™)for identifying protein-protein interactions between two specificproteins using the two-hybrid technique is commercially available fromClontech. This system can also be extended to map protein domainsinvolved in specific protein interactions as well as to pinpoint aminoacid residues that are crucial for these interactions.

Compounds that interfere with the interaction of EGFL7 and other intra-or extracellular components can be tested as follows: usually a reactionmixture is prepared containing EGFL7 and the intra- or extracellularcomponent under conditions and for a time allowing for the interactionand binding of the two products. To test the ability of a candidatecompound to inhibit binding, the reaction is run in the absence and inthe presence of the test compound. In addition, a placebo may be addedto a third reaction mixture, to serve as positive control. The binding(complex formation) between the test compound and the intra- orextracellular component present in the mixture is monitored as describedhereinabove. The formation of a complex in the control reaction(s) butnot in the reaction mixture containing the test compound indicates thatthe test compound interferes with the interaction of the test compoundand its reaction partner.

EGFL7 antagonists may be detected by combining EGFL7 and a potentialantagonist with membrane-bound EGFL7 polypeptide receptors orrecombinant receptors under appropriate conditions for a competitiveinhibition assay. EGFL7 can be labeled, such as by radioactivity, suchthat the number of EGFL7 polypeptide molecules bound to the receptor canbe used to determine the effectiveness of the potential antagonist. Thegene encoding the receptor can be identified by numerous methods knownto those of skill in the art, for example, ligand panning and FACSsorting. Coligan et al., Current Protocols in Immun. 1(2):Chapter 5(1991). Preferably, expression cloning is employed whereinpolyadenylated RNA is prepared from a cell responsive to EGFL7 and acDNA library created from this RNA is divided into pools and used totransfect COS cells or other cells that are not responsive to EGFL7.Transfected cells that are grown on glass slides are exposed to thelabeled EGFL7 polypeptide. EGFL7 can be labeled by a variety of meansincluding iodination or inclusion of a recognition site for asite-specific protein kinase. Following fixation and incubation, theslides are subjected to autoradiographic analysis. Positive pools areidentified and sub-pools are prepared and re-transfected using aninteractive sub-pooling and re-screening process, eventually yielding asingle clone that encodes the putative receptor.

As an alternative approach for receptor identification, the labeledEGFL7 polypeptide can be photoaffinity-linked with cell membrane orextract preparations that express the receptor molecule. Cross-linkedmaterial is resolved by PAGE and exposed to X-ray film. The labeledcomplex containing the receptor can be excised, resolved into peptidefragments, and subjected to protein micro-sequencing. The amino acidsequence obtained from micro-sequencing would be used to design a set ofdegenerate oligonucleotide probes to screen a cDNA library to identifythe gene encoding the putative receptor.

In another assay for antagonists, mammalian cells or a membranepreparation expressing the receptor would be incubated with the labeledEGFL7 polypeptide in the presence of the candidate compound. The abilityof the compound to enhance or block this interaction could then bemeasured.

The compositions useful in the treatment of cardiovascular, endothelial,and angiogenic disorders include, without limitation, antibodies, smallorganic and inorganic molecules, peptides, phosphopeptides, antisenseand ribozyme molecules, triple-helix molecules, etc., that inhibit theexpression and/or activity of the target gene product.

More specific examples of potential antagonists include anoligonucleotide that binds to the fusions of immunoglobulin with EGFL7,and, in particular, antibodies including, without limitation, poly- andmonoclonal antibodies and antibody fragments, single-chain antibodies,anti-idiotypic antibodies, and chimeric or humanized versions of suchantibodies or fragments, as well as human antibodies and antibodyfragments. Alternatively, a potential antagonist may be a closelyrelated protein, for example, a mutated form of EGFL7 that recognizesthe receptor but imparts no effect, thereby competitively inhibiting theaction of EGFL7.

Another potential EGFL7 antagonist is an antisense RNA or DNA constructprepared using antisense technology, where, e.g., an antisense RNA orDNA molecule acts to block directly the translation of mRNA byhybridizing to targeted mRNA and preventing protein translation.Antisense technology can be used to control gene expression throughtriple-helix formation or antisense DNA or RNA, both of which methodsare based on binding of a polynucleotide to DNA or RNA. For example, the5′ coding portion of the polynucleotide sequence, which encodes themature EGFL7 polypeptides herein, is used to design an antisense RNAoligonucleotide of from about 10 to 40 base pairs in length. A DNAoligonucleotide is designed to be complementary to a region of the geneinvolved in transcription (triple helix—see, Lee et al., Nucl. AcidsRes. 6:3073 (1979); Cooney et al., Science 241:456 (1988); Dervan etal., Science 251:1360 (1991)), thereby preventing transcription and theproduction of EGFL7. A sequence “complementary” to a portion of an RNA,as referred to herein, means a sequence having sufficientcomplementarity to be able to hybridize with the RNA, forming a stableduplex; in the case of double-stranded antisense nucleic acids, a singlestrand of the duplex DNA may thus be tested, or triplex helix formationmay be assayed. The ability to hybridize will depend on both the degreeof complementarity and the length of the antisense nucleic acid.Generally, the longer the hybridizing nucleic acid, the more basemismatches with an RNA it may contain and still form a stable duplex (ortriplex, as the case may be). One skilled in the art can ascertain atolerable degree of mismatch by use of standard procedures to determinethe melting point of the hybridized complex. The antisense RNAoligonucleotide hybridizes to the mRNA in vivo and blocks translation ofthe mRNA molecule into EGFL7 (antisense—Okano, Neurochem. 56:560 (1991);Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression (CRCPress: Boca Raton, Fla., 1988).

The antisense oligonucleotides can be DNA or RNA or chimeric mixtures orderivatives or modified versions thereof, single-stranded ordouble-stranded. The oligonucleotide can be modified at the base moiety,sugar moiety, or phosphate backbone, for example, to improve stabilityof the molecule, hybridization, etc. The oligonucleotide may includeother appended groups such as peptides (e.g., for targeting host cellreceptors in vivo), or agents facilitating transport across the cellmembrane (see, e.g., Letsinger, et al., Proc. Natl. Acad. Sci. U.S.A.86:6553-6556 (1989); Lemaitre, et al., Proc. Natl. Acad. Sci. U.S.A.84:648-652 (1987); PCT Publication No. WO88/09810, published Dec. 15,1988) or the blood-brain barrier (see, e.g., PCT Publication No.WO89/10134, published Apr. 25, 1988), hybridization-triggered cleavageagents (see, e.g., Krol et al., BioTechniques 6:958-976 (1988)) orintercalating agents (see, e.g., Zon, Pharm. Res. 5:539-549 (1988)). Tothis end, the oligonucleotide may be conjugated to another molecule,e.g., a peptide, hybridization triggered cross-linking agent, transportagent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified basemoiety which is selected from the group including but not limited to5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil,hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl)uracil, 5-carboxymethylaminomethyl-2-thiouridine,5-carboxymethylaminomethyluracil, dihydrouracil,beta-D-galactosylqueosine, inosine, N6-isopentenyladenine,1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine,2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine,7-methylguanine, 5-methylaminomethyluracil,5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine,5′-methoxycarboxymethyluracil, 5-methoxyuracil,2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v),wybutoxosine, pseudouracil, queosine, 2-thiocytosine,5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil,uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v),5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w,and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modifiedsugar moiety selected from the group including but not limited toarabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises atleast one modified phosphate backbone selected from the group consistingof a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, aphosphoramidate, a phosphordiamidate, a methylphosphonate, an alkylphosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an -anomericoligonucleotide. An -anomeric oligonucleotide forms specificdouble-stranded hybrids with complementary RNA in which, contrary to theusual -units, the strands run parallel to each other (Gautier, et al.,Nucl. Acids Res. 15:6625-6641 (1987)). The oligonucleotide is a2′-0-methylribonucleotide (Inoue, et al., Nucl. Acids Res. 15:6131-6148(1987)), or a chimeric RNA-DNA analogue (Inoue, et al., FEBS Lett.215:327-330 (1987)).

Oligonucleotides of the invention may be synthesized by standard methodsknown in the art, e.g., by use of an automated DNA synthesizer (such asare commercially available from Biosearch, Applied Biosystems, etc.). Asexamples, phosphorothioate oligonucleotides may be synthesized by themethod of Stein, et al. (Nucl. Acids Res. 16:3209 (1988)),methylphosphonate oligonucleotides can be prepared by use of controlledpore glass polymer supports (Sarin, et al., Proc. Natl. Acad. Sci.U.S.A. 85:7448-7451 (1988)), etc.

The oligonucleotides described above can also be delivered to cells suchthat the antisense RNA or DNA may be expressed in vivo to inhibitproduction of EGFL7. When antisense DNA is used,oligodeoxyribonucleotides derived from the translation-initiation site,e.g., between about −10 and +10 positions of the target gene nucleotidesequence, are preferred.

Antisense RNA or DNA molecules are generally at least about 5 bases inlength, about 10 bases in length, about 15 bases in length, about 20bases in length, about 25 bases in length, about 30 bases in length,about 35 bases in length, about 40 bases in length, about 45 bases inlength, about 50 bases in length, about 55 bases in length, about 60bases in length, about 65 bases in length, about 70 bases in length,about 75 bases in length, about 80 bases in length, about 85 bases inlength, about 90 bases in length, about 95 bases in length, about 100bases in length, or more.

Potential antagonists further include small molecules that bind to theactive site, the receptor binding site, or growth factor or otherrelevant binding site of EGFL7, thereby blocking the normal biologicalactivity of EGFL7. Examples of small molecules include, but are notlimited to, small peptides or peptide-like molecules, preferably solublepeptides, and synthetic non-peptidyl organic or inorganic compounds.

Additional potential antagonists are ribozymes, which are enzymatic RNAmolecules capable of catalyzing the specific cleavage of RNA. Ribozymesact by sequence-specific hybridization to the complementary target RNA,followed by endonucleolytic cleavage. Specific ribozyme cleavage siteswithin a potential RNA target can be identified by known techniques. Forfurther details see, e.g., Rossi, Current Biology 4:469471 (1994), andPCT publication No. WO 97/33551 (published Sep. 18, 1997).

While ribozymes that cleave mRNA at site specific recognition sequencescan be used to destroy target gene mRNAs, the use of hammerheadribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locationsdictated by flanking regions which form complementary base pairs withthe target mRNA. The sole requirement is that the target mRNA have thefollowing sequence of two bases: 5′-UG-3′. The construction andproduction of hammerhead ribozymes is well known in the art and isdescribed more fully in Myers, Molecular Biology and Biotechnology: AComprehensive Desk Reference, VCH Publishers, New York (1995), (seeespecially FIG. 4, page 833) and in Haseloff and Gerlach, Nature,334:585-591 (1988), which is incorporated herein by reference in itsentirety.

Preferably the ribozyme is engineered so that the cleavage recognitionsite is located near the 5′ end of the target gene mRNA, i.e., toincrease efficiency and minimize the intracellular accumulation ofnon-functional mRNA transcripts.

The ribozymes of the present invention also include RNAendoribonucleases (hereinafter “Cech-type ribozymes”) such as the onewhich occurs naturally in Tetrahymena thermophila (known as the IVS, orL-19 IVS RNA) and which has been extensively described by Thomas Cechand collaborators (Zaug, et al., Science, 224:574-578 (1984); Zaug andCech, Science, 231:470-475 (1986); Zaug, et al., Nature, 324:429-433(1986); published International patent application No. WO 88/04300 byUniversity Patents Inc.; Been and Cech, Cell, 47:207-216 (1986)). TheCech-type ribozymes have an eight base pair active site that hybridizesto a target RNA sequence whereafter cleavage of the target RNA takesplace. The invention encompasses those Cech-type ribozymes that targeteight base-pair active site sequences that are present in the targetgene.

As in the antisense approach, the ribozymes can be composed of modifiedoligonucleotides (e.g., for improved stability, targeting, etc.) andshould be delivered to cells that express the target gene in vivo. Apreferred method of delivery involves using a DNA construct “encoding”the ribozyme under the control of a strong constitutive pol III or polII promoter, so that transfected cells will produce sufficientquantities of the ribozyme to destroy endogenous target gene messagesand inhibit translation. Because ribozymes, unlike antisense molecules,are catalytic, a lower intracellular concentration is required forefficiency.

Nucleic acid molecules in triple-helix formation used to inhibittranscription should be single-stranded and composed ofdeoxynucleotides. The base composition of these oligonucleotides isdesigned such that it promotes triple-helix formation via Hoogsteenbase-pairing rules, which generally require sizeable stretches ofpurines or pyrimidines on one strand of a duplex. For further detailssee, e.g., PCT publication No. WO 97/33551, supra.

These small molecules can be identified by any one or more of thescreening assays discussed hereinabove and/or by any other screeningtechniques well known for those skilled in the art.

Types of Cardiovascular. Endothelial, and Angiogenic Disorders to beTreated

EGFL7 or agonists thereto that have activity in the cardiovascular,angiogenic, and endothelial assays described herein, are likely to havetherapeutic uses in a variety of cardiovascular, endothelial, andangiogenic disorders, including systemic disorders that affect vessels,such as diabetes mellitus. Their therapeutic utility could includediseases of the arteries, capillaries, veins, and/or lymphatics.Examples of treatments hereunder include treating muscle wastingdisease, treating osteoporosis, aiding in implant fixation to stimulatethe growth of cells around the implant and therefore facilitate itsattachment to its intended site, increasing IGF stability in tissues orin serum, if applicable, and increasing binding to the IGF receptor(since IGF has been shown in vitro to enhance human marrow erythroid andgranulocytic progenitor cell growth).

EGFL7 or agonists thereto may also be employed to stimulateerythropoiesis or granulopoiesis, to stimulate wound healing or tissueregeneration and associated therapies concerned with re-growth oftissue, such as connective tissue, skin, bone, cartilage, muscle, lung,or kidney, to promote angiogenesis, to stimulate or inhibit migration ofendothelial cells, and to proliferate the growth of vascular smoothmuscle and endothelial cell production. The increase in angiogenesismediated by EGFL7 or agonist would be beneficial to ischemic tissues andto collateral coronary development in the heart subsequent to coronarystenosis. Antagonists are used to inhibit the action of suchpolypeptides, for example, to limit the production of excess connectivetissue during wound healing or pulmonary fibrosis if EGFL7 promotes suchproduction: This would include treatment of acute myocardial infarctionand heart failure.

Specific types of diseases are described below, where EGFL7 may serve asuseful for vascular-related drug targeting or as therapeutic targets forthe treatment or prevention of the disorders. Atherosclerosis is adisease characterized by accumulation of plaques of intimal thickeningin arteries, due to accumulation of lipids, proliferation of smoothmuscle cells, and formation of fibrous tissue within the arterial wall.The disease can affect large, medium, and small arteries in any organ.Changes in endothelial and vascular smooth muscle cell function areknown to play an important role in modulating the accumulation andregression of these plaques.

Hypertension is characterized by raised vascular pressure in thesystemic arterial, pulmonary arterial, or portal venous systems.Elevated pressure may result from or result in impaired endothelialfunction and/or vascular disease.

Inflammatory vasculitides include giant cell arteritis, Takayasu'sarteritis, polyarteritis nodosa (including the microangiopathic form),Kawasaki's disease, microscopic polyangiitis, Wegener's granulomatosis,and a variety of infectious-related vascular disorders (includingHenoch-Schonlein prupura). Altered endothelial cell function has beenshown to be important in these diseases.

Reynaud's disease and Reynaud's phenomenon are characterized byintermittent abnormal impairment of the circulation through theextremities on exposure to cold. Altered endothelial cell function hasbeen shown to be important in this disease.

Aneurysms are saccular or fusiform dilatations of the arterial or venoustree that are associated with altered endothelial cell and/or vascularsmooth muscle cells.

Arterial restenosis (restenosis of the arterial wall) may occurfollowing angioplasty as a result of alteration in the function andproliferation of endothelial and vascular smooth muscle cells.

Thrombophlebitis and lymphangitis are inflammatory disorders of veinsand lymphatics, respectively, that may result from, and/or in, alteredendothelial cell function. Similarly, lymphedema is a conditioninvolving impaired lymphatic vessels resulting from endothelial cellfunction.

The family of benign and malignant vascular tumors are characterized byabnormal proliferation and growth of cellular elements of the vascularsystem. For example, lymphangiomas are benign tumors of the lymphaticsystem that are congenital, often cystic, malformations of thelymphatics that usually occur in newborns. Cystic tumors tend to growinto the adjacent tissue. Cystic tumors usually occur in the cervicaland axillary region. They can also occur in the soft tissue of theextremities. The main symptoms are dilated, sometimes reticular,structured lymphatics and lymphocysts surrounded by connective tissue.Lymphangiomas are assumed to be caused by improperly connected embryoniclymphatics or their deficiency. The result is impaired local lymphdrainage. Griener et al., Lymphology 4:140-144 (1971).

Another use for EGFL7 antagonists is in the prevention of tumorangiogenesis, which involves vascularization of a tumor to enable it togrowth and/or metastasize. This process is dependent on the growth ofnew blood vessels. Examples of neoplasms and related conditions thatinvolve tumor angiogenesis include squamous cell cancer, lung cancer(including small-cell lung cancer, non-small cell lung cancer,adenocarcinoma of the lung, and squamous carcinoma of the lung), cancerof the peritoneum, hepatocellular cancer, gastric or stomach cancer(including gastrointestinal cancer), pancreatic cancer, glioblastoma,cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma,breast cancer, colon cancer, colorectal cancer, endometrial or uterinecarcinoma, salivary gland carcinoma, kidney or renal cancer, livercancer, prostate cancer, vulval cancer, thyroid cancer, hepaticcarcinoma and various types of head and neck cancer, as well as B-celllymphoma (including low grade/follicular non-Hodgkin's lymphoma (NHL);small lymphocytic (SL) NHL; intermediate grade/follicular NHL;intermediate grade diffuse NHL; high grade immunoblastic NHL; high gradelymphoblastic NHL; high grade small non-cleaved cell NHL; bulky diseaseNHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom'sMacroglobulinemia); chronic lymphocytic leukemia (CLL); acutelymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblasticleukemia; and post-transplant lymphoproliferative disorder (PTLD), aswell as abnormal vascular proliferation associated with phakomatoses,edema (such as that associated with brain tumors), and Meigs' syndrome.

The EGFL7 antagonists can also be useful in treating intraocularneovascular diseases including, but not limited to, proliferativeretinopathies, choroidal neovascularization (CNV), age-related maculardegeneration (AMD), diabetic and other ischemia-related retinopathies,diabetic macular edema, pathological myopia, von Hippel-Lindau disease,histoplasmosis of the eye, Central Retinal Vein Occlusion (CRVO),corneal neovascularization, retinal neovascularization, etc.

Rheumatoid arthritis is a further indication. Blood vessel growth andtargeting of inflammatory cells through the vasculature is an importantcomponent in the pathogenesis of rheumatoid and sero-negative forms ofarthritis.

In view of the above, EGFL7, agonists or antagonists thereof describedherein, which are shown to alter or impact endothelial cell function andmigration, are likely to play an important role in the etiology andpathogenesis of many or all of the disorders noted above, and as suchcan serve as therapeutic targets to augment or inhibit these processesor for vascular-related drug targeting in these disorders.

Administration Protocols, Schedules, Doses, and Formulations

The molecules herein and agonists and antagonists thereto arepharmaceutically useful as a prophylactic and therapeutic agent forvarious disorders and diseases as set forth above.

Therapeutic compositions of EGFL7s or agonists or antagonists areprepared for storage by mixing the desired molecule having theappropriate degree of purity with optional pharmaceutically acceptablecarriers, excipients, or stabilizers (Remington's PharmaceuticalSciences, 16th edition, Osol, A. ed. (1980)), in the form of lyophilizedformulations or aqueous solutions. Acceptable carriers, excipients, orstabilizers are nontoxic to recipients at the dosages and concentrationsemployed, and include buffers such as phosphate, citrate, and otherorganic acids; antioxidants including ascorbic acid and methionine;preservatives (such as octadecyldimethylbenzyl ammonium chloride;hexamethonium chloride; benzalkonium chloride, benzethonium chloride;phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol);low molecular weight (less than about 10 residues) polypeptides;proteins, such as serum albumin, gelatin, or immunoglobulins;hydrophilic polymers such as polyvinylpyrrolidone; amino acids such asglycine, glutamine, asparagine, histidine, arginine, or lysine;monosaccharides, disaccharides, and other carbohydrates includingglucose, mannose, or dextrins; chelating agents such as EDTA; sugarssuch as sucrose, mannitol, trehalose or sorbitol; salt-formingcounter-ions such as sodium; metal complexes (e.g., Zn-proteincomplexes); and/or non-ionic surfactants such as TWEEN™, PLURONICS™ orpolyethylene glycol (PEG).

Additional examples of such carriers include ion exchangers, alumina,aluminum stearate, lecithin, serum proteins, such as human serumalbumin, buffer substances such as phosphates, glycine, sorbic acid,potassium sorbate, partial glyceride mixtures of saturated vegetablefatty acids, water, salts, or electrolytes such as protamine sulfate,disodium hydrogen phosphate, potassium hydrogen phosphate, sodiumchloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, and polyethylene glycol.Carriers for topical or gel-based forms of agonist or antagonist includepolysaccharides such as sodium carboxymethylcellulose ormethylcellulose, polyvinylpyrrolidone, polyacrylates,polyoxyethylene-polyoxypropylene-block polymers, polyethylene glycol,and wood wax alcohols. For all administrations, conventional depot formsare suitably used. Such forms include, for example, microcapsules,nano-capsules, liposomes, plasters, inhalation forms, nose sprays,sublingual tablets, and sustained-release preparations. EGFL7s oragonists or antagonists will typically be formulated in such vehicles ata concentration of about 0.1 mg/ml to 100 mg/ml.

Another formulation comprises incorporating EGFL7 or agonist orantagonist thereof into formed articles. Such articles can be used inmodulating endothelial cell growth and angiogenesis. In addition, tumorinvasion and metastasis may be modulated with these articles.

EGFL7 polypeptides or agonists or antagonists to be used for in vivoadministration must be sterile. This is readily accomplished byfiltration through sterile filtration membranes, prior to or followinglyophilization and reconstitution. EGFL7 polypeptides ordinarily will bestored in lyophilized form or in solution if administered systemically.If in lyophilized form, EGFL7 or agonist or antagonist thereto istypically formulated in combination with other ingredients forreconstitution with an appropriate diluent at the time for use. Anexample of a liquid formulation of EGFL7 or agonist or antagonist is asterile, clear, colorless unpreserved solution filled in a single-dosevial for subcutaneous injection. Preserved pharmaceutical compositionssuitable for repeated use may contain, for example, depending mainly onthe indication and type of polypeptide:

EGFL7 polypeptide or agonist or antagonist thereto;

a buffer capable of maintaining the pH in a range of maximum stabilityof the polypeptide or other molecule in solution, preferably about 4-8;

a detergent/surfactant primarily to stabilize the polypeptide ormolecule against agitation-induced aggregation;

an isotonifier;

a preservative selected from the group of phenol, benzyl alcohol and abenzethonium halide, e.g., chloride; and

water.

If the detergent employed is non-ionic, it may, for example, bepolysorbates (e.g., POLYSORBATE™ (TWEEN™) 20, 80, etc.) or poloxamers(e.g., POLOXAMER™ 188). The use of non-ionic surfactants permits theformulation to be exposed to shear surface stresses without causingdenaturation of the polypeptide. Further, such surfactant-containingformulations may be employed in aerosol devices such as those used in apulmonary dosing, and needleless jet injector guns (see, e.g., EP257,956).

An isotonifier may be present to ensure isotonicity of a liquidcomposition of EGFL7 or agonist or antagonist thereto, and includespolyhydric sugar alcohols, preferably trihydric or higher sugaralcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol, andmannitol. These sugar alcohols can be used alone or in combination.Alternatively, sodium chloride or other appropriate inorganic salts maybe used to render the solutions isotonic.

The buffer may, for example, be an acetate, citrate, succinate, orphosphate buffer depending on the pH desired. The pH of one type ofliquid formulation of this invention is buffered in the range of about 4to 8, preferably about physiological pH.

The preservatives phenol, benzyl alcohol and benzethonium halides, e.g.,chloride, are known antimicrobial agents that may be employed.

Therapeutic polypeptide compositions described herein generally areplaced into a container having a sterile access port, for example, anintravenous solution bag or vial having a stopper pierceable by ahypodermic injection needle. The formulations are preferablyadministered as repeated intravenous (i.v.), subcutaneous (s.c.), orintramuscular (i.m.) injections, or as aerosol formulations suitable forintranasal or intrapulmonary delivery (for intrapulmonary delivery see,e.g., EP 257,956).

Therapeutic polypeptides can also be administered in the form ofsustained-released preparations. Suitable examples of sustained-releasepreparations include semipermeable matrices of solid hydrophobicpolymers containing the protein, which matrices are in the form ofshaped articles, e.g., films, or microcapsules. Examples ofsustained-release matrices include polyesters, hydrogels (e.g.,poly(2-hydroxyethyl-methacrylate) as described by Langer et al., J.Biomed. Mater. Res. 15:167-277 (1981) and Langer, Chem. Tech. 12:98-105(1982) or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919, EP58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate(Sidman et al., Biopolymers 22:547-556 (1983)), non-degradableethylene-vinyl acetate (Langer et al., supra), degradable lacticacid-glycolic acid copolymers such as the Lupron Depot™ (injectablemicrospheres composed of lactic acid-glycolic acid copolymer andleuprolide acetate), and poly-D-(−)-3-hydroxybutyric acid (EP 133,988).

While polymers such as ethylene-vinyl acetate and lactic acid-glycolicacid enable release of molecules for over 100 days, certain hydrogelsrelease proteins for shorter time periods. When encapsulated proteinsremain in the body for a long time, they may denature or aggregate as aresult of exposure to moisture at 37□ C., resulting in a loss ofbiological activity and possible changes in immunogenicity. Rationalstrategies can be devised for protein stabilization depending on themechanism involved. For example, if the aggregation mechanism isdiscovered to be intermolecular S—S bond formation throughthio-disulfide interchange, stabilization may be achieved by modifyingsulfhydryl residues, lyophilizing from acidic solutions, controllingmoisture content, using appropriate additives, and developing specificpolymer matrix compositions.

Sustained-release EGFL7 polypeptide compositions also includeliposomally entrapped EGFL7 polypeptides. Liposomes containing the EGFL7polypeptide are prepared by methods known per se: DE 3,218,121; Epsteinet al., Proc. Natl. Acad. Sci. USA 82:3688-3692 (1985); Hwang et al.,Proc. Natl. Acad. Sci. USA 77:4030-4034 (1980); EP 52,322; EP 36,676; EP88,046; EP 143,949; EP 142,641; Japanese patent application 83-118008;U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily theliposomes are of the small (about 200-800 Angstroms) unilamellar type inwhich the lipid content is greater than about 30 mol. % cholesterol, theselected proportion being adjusted for the optimal therapy.

The therapeutically effective dose of EGFL7 or agonist or antagonistthereto will, of course, vary depending on such factors as thepathological condition to be treated (including prevention), the methodof administration, the type of compound being used for treatment, anyco-therapy involved, the patient's age, weight, general medicalcondition, medical history, etc., and its determination is well withinthe skill of a practicing physician. Accordingly, it will be necessaryfor the therapist to titer the dosage and modify the route ofadministration as required to obtain the maximal therapeutic effect. IfEGFL7 has a narrow host range, for the treatment of human patientsformulations comprising human EGFL7 polypeptide, more preferablynative-sequence human EGFL7 polypeptide, are preferred. The clinicianwill administer EGFL7 until a dosage is reached that achieves thedesired effect for treatment of the condition in question. For example,if the objective is the treatment of CHF, the amount would be one thatinhibits the progressive cardiac hypertrophy associated with thiscondition. The progress of this therapy is easily monitored by echocardiography. Similarly, in patients with hypertrophic cardiomyopathy,EGFL7 can be administered on an empirical basis.

With the above guidelines, the effective dose generally is within therange of from about 0.001 to about 1.0 mg/kg, more preferably about0.01-1.0 mg/kg, most preferably about 0.01-0.1 mg/kg.

For non-oral use in treating human adult hypertension, it isadvantageous to administer EGFL7 in the form of an injection at about0.01 to 50 mg, preferably about 0.05 to 20 mg, most preferably 1 to 20mg, per kg body weight, 1 to 3 times daily by intravenous injection. Fororal administration, a molecule based on EGFL7 is preferablyadministered at about 5 mg to 1 g, preferably about 10 to 100 mg, per kgbody weight, 1 to 3 times daily. It should be appreciated that endotoxincontamination should be kept minimally at a safe level, for example,less than 0.5 ng/mg protein. Moreover, for human administration, theformulations preferably meet sterility, pyrogenicity, general safety,and purity as required by FDA Office and Biologics standards.

The dosage regimen of a pharmaceutical composition containing EGFL7 tobe used in tissue regeneration will be determined by the attendingphysician considering various factors that modify the action of thepolypeptides, e.g., amount of tissue weight desired to be formed, thesite of damage, the condition of the damaged tissue, the size of awound, type of damaged tissue (e.g., bone), the patient's age, sex, anddiet, the severity of any infection, time of administration, and otherclinical factors. The dosage may vary with the type of matrix used inthe reconstitution and with inclusion of other proteins in thepharmaceutical composition. For example, the addition of other knowngrowth factors, such as IGF-I, to the final composition may also affectthe dosage. Progress can be monitored by periodic assessment oftissue/bone growth and/or repair, for example, X-rays, histomorphometricdeterminations, and tetracycline labeling.

The route of EGFL7 polypeptide or antagonist or agonist administrationis in accord with known methods, e.g., by injection or infusion byintravenous, intramuscular, intracerebral, intraperitoneal,intracerobrospinal, subcutaneous, intraocular, intraarticular,intrasynovial, intrathecal, oral, topical, or inhalation routes, or bysustained-release systems as noted below. EGFL7 or agonist orantagonists thereof also are suitably administered by intratumoral,peritumoral, intralesional, or perilesional routes, to exert local aswell as systemic therapeutic effects. The intraperitoneal route isexpected to be particularly useful, for example, in the treatment ofovarian tumors.

If a peptide or small molecule is employed as an antagonist or agonist,it is preferably administered orally or non-orally in the form of aliquid or solid to mammals.

Examples of pharmacologically acceptable salts of molecules that formsalts and are useful hereunder include alkali metal salts (e.g., sodiumsalt, potassium salt), alkaline earth metal salts (e.g., calcium salt,magnesium salt), ammonium salts, organic base salts (e.g., pyridinesalt, triethylamine salt), inorganic acid salts (e.g., hydrochloride,sulfate, nitrate), and salts of organic acid (e.g., acetate, oxalate,p-toluenesulfonate).

For compositions herein that are useful for bone, cartilage, tendon, orligament regeneration, the therapeutic method includes administering thecomposition topically, systemically, or locally as an implant or device.When administered, the therapeutic composition for use is in apyrogen-free, physiologically acceptable form. Further, the compositionmay desirably be encapsulated or injected in a viscous form for deliveryto the site of bone, cartilage, or tissue damage. Topical administrationmay be suitable for wound healing and tissue repair. Preferably, forbone and/or cartilage formation, the composition would include a matrixcapable of delivering the protein-containing composition to the site ofbone and/or cartilage damage, providing a structure for the developingbone and cartilage and preferably capable of being resorbed into thebody. Such matrices may be formed of materials presently in use forother implanted medical applications.

The choice of matrix material is based on biocompatibility,biodegradability, mechanical properties, cosmetic appearance, andinterface properties. The particular application of the compositionswill define the appropriate formulation. Potential matrices for thecompositions may be biodegradable and chemically defined calciumsulfate, tricalcium phosphate, hydroxyapatite, polylactic acid,polyglycolic acid, and polyanhydrides. Other potential materials arebiodegradable and biologically well-defined, such as bone or dermalcollagen. Further matrices are comprised of pure proteins orextracellular matrix components. Other potential matrices arenonbiodegradable and chemically defined, such as sinteredhydroxyapatite, bioglass, aluminates, or other ceramics. Matrices may becomprised of combinations of any of the above-mentioned types ofmaterial, such as polylactic acid and hydroxyapatite or collagen andtricalcium phosphate. The bioceramics may be altered in composition,such as in calcium-aluminate-phosphate and processing to alter poresize, particle size, particle shape, and biodegradability.

One specific embodiment is a 50:50 (mole weight) copolymer of lacticacid and glycolic acid in the form of porous particles having diametersranging from 150 to 800 microns. In some applications, it will be usefulto utilize a sequestering agent, such as carboxymethyl cellulose orautologous blood clot, to prevent the polypeptide compositions fromdisassociating from the matrix.

One suitable family of sequestering agents is cellulosic materials suchas alkylcelluloses (including hydroxyalkylcelluloses), includingmethylcellulose, ethylcellulose, hydoxyethylcellulose,hydroxypropylcellulose, hydroxypropylmethylcellulose, andcarboxymethylcellulose, one preferred being cationic salts ofcarboxymethylcellulose (CMC). Other preferred sequestering agentsinclude hyaluronic acid, sodium alginate, poly(ethylene glycol),polyoxyethylene oxide, carboxyvinyl polymer, and poly(vinyl alcohol).The amount of sequestering agent useful herein is 0.5-20 wt %,preferably 1-10 wt %, based on total formulation weight, whichrepresents the amount necessary to prevent desorption of the polypeptide(or its antagonist) from the polymer matrix and to provide appropriatehandling of the composition, yet not so much that the progenitor cellsare prevented from infiltrating the matrix, thereby providing thepolypeptide (or its antagonist) the opportunity to assist the osteogenicactivity of the progenitor cells.

Combination Therapies

The effectiveness of EGFL7 or an agonist or antagonist thereof inpreventing or treating the disorder in question may be improved byadministering the active agent serially or in combination with anotheragent that is effective for those purposes, either in the samecomposition or as separate compositions.

For example, EGFL7 antagonists used to treat angiogenesis associatedconditions such as cancer or ocular diseases may be combined withcytotoxic, chemotherapeutic, or anti-angiogenic agents as identifiedabove. In a tumor model, EGFL7 was found to remain in the tracks ofregressed tumor vessels after the tumor was treated with an anti-VEGFantibody (see Examples). Not wishing to be bound by a particular theory,it is possible that EGFL7 acts to support EC migration along theexisting ECM tracks, and thus assists in tumor vessel regrowthsubsequent to an anti-angiogenesis treatment. Therefore, it is desirableto use EGFL7 antagonists in combination with an anti-angiogenic agent toenhance or sensitize the activity of the anti-angiogenic agent. In apreferred embodiment, the EGFL7 antagonist is used in combination withthe anti-VEGF antibody bevacizumab to enhance its anti-tumor efficacy.

The effective amounts of the therapeutic agents administered incombination with EGFL7 or agonist or antagonist thereof will be at thephysician's or veterinarian's discretion. Dosage administration andadjustment is done to achieve maximal management of the conditions to betreated. For example, for treating hypertension, these amounts ideallytake into account use of diuretics or digitalis, and conditions such ashyper- or hypotension, renal impairment, etc. The dose will additionallydepend on such factors as the type of the therapeutic agent to be usedand the specific patient being treated. Typically, the amount employedwill be the same dose as that used, if the given therapeutic agent isadministered without EGFL7.

Articles of Manufacture

An article of manufacture such as a kit containing EGFL7 or agonists orantagonists thereof useful for the diagnosis or treatment of thedisorders described above comprises at least a container and a label.Suitable containers include, for example, bottles, vials, syringes, andtest tubes. The containers may be formed from a variety of materialssuch as glass or plastic. The container holds a composition that iseffective for diagnosing or treating the condition and may have asterile access port (for example, the container may be an intravenoussolution bag or a vial having a stopper pierceable by a hypodermicinjection needle). The active agent in the composition is EGFL7 or anagonist or antagonist thereto. The label on, or associated with, thecontainer indicates that the composition is used for diagnosing ortreating the condition of choice. The article of manufacture may furthercomprise a second container comprising a pharmaceutically-acceptablebuffer, such as phosphate-buffered saline, Ringer's solution, anddextrose solution. It may further include other materials desirable froma commercial and user standpoint, including other buffers, diluents,filters, needles, syringes, and package inserts with instructions foruse. The article of manufacture may also comprise a second or thirdcontainer with another active agent as described above.

EGFL7 Antibodies

Some of the most promising drug candidates according to the presentinvention are antibodies and antibody fragments that may inhibit theproduction or the gene product of the gene identified herein and/orreduce the activity of the gene products.

Polyclonal Antibodies

Methods of preparing polyclonal antibodies are known to the skilledartisan. Polyclonal antibodies can be raised in a mammal, for example,by one or more injections of an immunizing agent and, if desired, anadjuvant. Typically, the immunizing agent and/or adjuvant will beinjected in the mammal by multiple subcutaneous or intraperitonealinjections. The immunizing agent may include the EGFL7 polypeptide or afusion protein thereof. It may be useful to conjugate the immunizingagent to a protein known to be immunogenic in the mammal beingimmunized. Examples of such immunogenic proteins include, but are notlimited to, keyhole limpet hemocyanin, serum albumin, bovinethyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants thatmay be employed include Freund's complete adjuvant and MPL-TDM adjuvant(monophosphoryl Lipid A or synthetic trehalose dicorynomycolate). Theimmunization protocol may be selected by one skilled in the art withoutundue experimentation.

Monoclonal Antibodies

The anti-EGFL7 antibodies may, alternatively, be monoclonal antibodies.Monoclonal antibodies may be prepared using hybridoma methods, such asthose described by Kohler and Milstein, Nature 256:495 (1975). In ahybridoma method, a mouse, hamster, or other appropriate host animal istypically immunized with an immunizing agent to elicit lymphocytes thatproduce or are capable of producing antibodies that will specificallybind to the immunizing agent. Alternatively, the lymphocytes may beimmunized in vitro.

The immunizing agent will typically include the EGFL7 polypeptide or afusion protein thereof. Generally, either peripheral blood lymphocytes(“PBLs”) are used if cells of human origin are desired, or spleen cellsor lymph node cells are used if non-human mammalian sources are desired.The lymphocytes are then fused with an immortalized cell line using asuitable fusing agent, such as polyethylene glycol, to form a hybridomacell. Goding, Monoclonal Antibodies: Principles and Practice (New York:Academic Press, 1986), pp. 59-103. Immortalized cell lines are usuallytransformed mammalian cells, particularly myeloma cells of rodent,bovine, and human origin. Usually, rat or mouse myeloma cell lines areemployed. The hybridoma cells may be cultured in a suitable culturemedium that preferably contains one or more substances that inhibit thegrowth or survival of the unfused, immortalized cells. For example, ifthe parental cells lack the enzyme hypoxanthine guanine phosphoribosyltransferase (HGPRT or HPRT), the culture medium for the hybridomastypically will include hypoxanthine, aminopterin, and thymidine (“HATmedium”), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently,support stable high-level expression of antibody by the selectedantibody-producing cells, and are sensitive to a medium such as HATmedium. More preferred immortalized cell lines are murine myeloma lines,which can be obtained, for instance, from the Salk Institute CellDistribution Center, San Diego, California and the American Type CultureCollection, Manassas, Virginia. Human myeloma and mouse-humanheteromyeloma cell lines also have been described for the production ofhuman monoclonal antibodies. Kozbor, J. Immunol. 133:3001 (1984);Brodeur et al., Monoclonal Antibody Production Techniques andApplications (Marcel Dekker, Inc.: New York, 1987) pp. 51-63.

The culture medium in which the hybridoma cells are cultured can then beassayed for the presence of monoclonal antibodies directed against theEGFL7 polypeptide. Preferably, the binding specificity of monoclonalantibodies produced by the hybridoma cells is determined byimmunoprecipitation or by an in vitro binding assay, such asradioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).Such techniques and assays are known in the art. The binding affinity ofthe monoclonal antibody can, for example, be determined by the Scatchardanalysis of Munson and Pollard, Anal. Biochem. 107:220 (1980).

After the desired hybridoma cells are identified, the clones may besubcloned by limiting dilution procedures and grown by standard methods.Goding, supra. Suitable culture media for this purpose include, forexample, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium.Alternatively, the hybridoma cells may be grown in vivo as ascites in amammal.

The monoclonal antibodies secreted by the subclones may be isolated orpurified from the culture medium or ascites fluid by conventionalimmunoglobulin purification procedures such as, for example, proteinA-Sepharose, hydroxylapatite chromatography, gel electrophoresis,dialysis, or affinity chromatography.

The monoclonal antibodies may also be made by recombinant DNA methods,such as those described in U.S. Pat. No. 4,816,567. DNA encoding themonoclonal antibodies of the invention can be readily isolated andsequenced using conventional procedures (e.g., by using oligonucleotideprobes that are capable of binding specifically to genes encoding theheavy and light chains of murine antibodies). The hybridoma cells of theinvention serve as a preferred source of such DNA. Once isolated, theDNA may be placed into expression vectors, which are then transfectedinto host cells such as simian COS cells, Chinese hamster ovary (CHO)cells, or myeloma cells that do not otherwise produce immunoglobulinprotein, to obtain the synthesis of monoclonal antibodies in therecombinant host cells. The DNA also may be modified, for example, bysubstituting the coding sequence for human heavy- and light-chainconstant domains in place of the homologous murine sequences (U.S. Pat.No. 4,816,567; Morrison et al., supra) or by covalently joining to theimmunoglobulin coding sequence all or part of the coding sequence for anon-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptidecan be substituted for the constant domains of an antibody of theinvention, or can be substituted for the variable domains of oneantigen-combining site of an antibody of the invention to create achimeric bivalent antibody.

The antibodies may be monovalent antibodies. Methods for preparingmonovalent antibodies are well known in the art. For example, one methodinvolves recombinant expression of immunoglobulin light chain andmodified heavy chain. The heavy chain is truncated generally at anypoint in the Fc region so as to prevent heavy-chain crosslinking.Alternatively, the relevant cysteine residues are substituted withanother amino acid residue or are deleted so as to prevent crosslinking.

In vitro methods are also suitable for preparing monovalent antibodies.Digestion of antibodies to produce fragments thereof, particularly Fabfragments, can be accomplished using routine techniques known in theart.

Human and Humanized Antibodies

The anti-EGFL7 antibodies may further comprise humanized antibodies orhuman antibodies. Humanized forms of non-human (e.g., murine) antibodiesare chimeric immunoglobulins, immunoglobulin chains, or fragmentsthereof (such as Fv, Fab, Fab′, F(ab′)₂, or other antigen-bindingsubsequences of antibodies) that contain minimal sequence derived fromnon-human immunoglobulin. Humanized antibodies include humanimmunoglobulins (recipient antibody) in which residues from a CDR of therecipient are replaced by residues from a CDR of a non-human species(donor antibody) such as mouse, rat, or rabbit having the desiredspecificity, affinity, and capacity. In some instances, Fv frameworkresidues of the human immunoglobulin are replaced by correspondingnon-human residues. Humanized antibodies may also comprise residues thatare found neither in the recipient antibody nor in the imported CDR orframework sequences. In general, the humanized antibody will comprisesubstantially all of at least one, and typically two, variable domains,in which all or substantially all of the CDR regions correspond to thoseof a non-human immunoglobulin, and all or substantially all of the FRregions are those of a human immunoglobulin consensus sequence. Thehumanized antibody preferably also will comprise at least a portion ofan immunoglobulin constant region (Fc), typically that of a humanimmunoglobulin. Jones et al., Nature 321:522-525 (1986); Riechmann etal., Nature 332:323-329 (1988); Presta, Curr. Op. Struct. Biol.2:593-596 (1992).

Methods for humanizing non-human antibodies are well known in the art.Generally, a humanized antibody has one or more amino acid residuesintroduced into it from a source that is non-human. These non-humanamino acid residues are often referred to as “import” residues, whichare typically taken from an “import” variable domain. Humanization canbe essentially performed following the method of Winter and co-workers(Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature332:323-327 (1988); Verhoeyen et al., Science 239:1534-1536 (1988)), bysubstituting rodent CDRs or CDR sequences for the correspondingsequences of a human antibody. Accordingly, such “humanized” antibodiesare chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantiallyless than an intact human variable domain has been substituted by thecorresponding sequence from a non-human species. In practice, humanizedantibodies are typically human antibodies in which some CDR residues andpossibly some FR residues are substituted by residues from analogoussites in rodent antibodies.

Human antibodies can also be produced using various techniques known inthe art, including phage display libraries. Hoogenboom and Winter, J.Mol. Biol. 227:381 (1991); Marks et al., J. Mol. Biol. 222:581 (1991).The techniques of Cole et al. and Boerner et al. are also available forthe preparation of human monoclonal antibodies. Cole et al., MonoclonalAntibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner etal., J. Immunol. 147(1):86-95 (1991). Similarly, human antibodies can bemade by introducing human immunoglobulin loci into transgenic animals,e.g., mice in which the endogenous immunoglobulin genes have beenpartially or completely inactivated. Upon challenge, human antibodyproduction is observed that closely resembles that seen in humans in allrespects, including gene rearrangement, assembly, and antibodyrepertoire. This approach is described, for example, in U.S. Pat. Nos.5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; and 5,661,016,and in the following scientific publications: Marks et al.,Bio/Technology 10:779-783 (1992); Lonberg et al., Nature 368:856-859(1994); Morrison, Nature, 368:812-813 (1994); Fishwild et al., NatureBiotechnology 14:845-851 (1996); Neuberger, Nature Biotechnology 14:826(1996); Lonberg and Huszar, Intern. Rev. Immunol. 13:65-93 (1995).

Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized,antibodies that have binding specificities for at least two differentantigens. In the present case, one of the binding specificities is forthe EGFL7 polypeptide, the other one is for any other antigen, andpreferably for a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art.Traditionally, the recombinant production of bispecific antibodies isbased on the co-expression of two immunoglobulin heavy-chain/light-chainpairs, where the two heavy chains have different specificities. Milsteinand Cuello, Nature 305:537-539 (1983). Because of the random assortmentof immunoglobulin heavy and light chains, these hybridomas (quadromas)produce a potential mixture of ten different antibody molecules, ofwhich only one has the correct bispecific structure. The purification ofthe correct molecule is usually accomplished by affinity chromatographysteps. Similar procedures are disclosed in WO 93/08829, published 13 May1993, and in Traunecker et al., EMBO J. 10:3655-3659 (1991).

Antibody variable domains with the desired binding specificities(antibody-antigen combining sites) can be fused to immunoglobulinconstant-domain sequences. The fusion preferably is with animmunoglobulin heavy-chain constant domain, comprising at least part ofthe hinge, CH2, and CH3 regions. It is preferred to have the firstheavy-chain constant region (CH1) containing the site necessary forlight-chain binding present in at least one of the fusions. DNAsencoding the immunoglobulin heavy-chain fusions and, if desired, theimmunoglobulin light chain, are inserted into separate expressionvectors, and are co-transfected into a suitable host organism. Forfurther details of generating bispecific antibodies, see, for example,Suresh et al., Methods in Enzymology 121:210 (1986).

Heteroconjugate Antibodies

Heteroconjugate antibodies are composed of two covalently joinedantibodies. Such antibodies have, for example, been proposed to targetimmune-system cells to unwanted cells (U.S. Pat. No. 4,676,980), and fortreatment of HIV infection. WO 91/00360; WO 92/200373; EP 03089. It iscontemplated that the antibodies may be prepared in vitro using knownmethods in synthetic protein chemistry, including those involvingcrosslinking agents. For example, immunotoxins may be constructed usinga disulfide-exchange reaction or by forming a thioether bond. Examplesof suitable reagents for this purpose include iminothiolate andmethyl4-mercaptobutyrimidate and those disclosed, for example, in U.S.Pat. No. 4,676,980.

Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibodyconjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin(e.g., an enzymatically active toxin of bacterial, fungal, plant, oranimal origin, or fragments thereof), or a radioactive isotope (i.e., aradioconjugate).

Chemotherapeutic agents useful in the generation of suchimmunoconjugates have been described above. Enzymatically active toxinsand fragments thereof that can be used include diphtheria A chain,nonbinding active fragments of diphtheria toxin, exotoxin A chain (fromPseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain,alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolacaamericana proteins (PAPI, PAPII, and PAP-S), momordica charantiainhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin,mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. Avariety of radionuclides are available for the production ofradioconjugated antibodies. Examples include ²¹²Bi, ¹³¹I, ¹³¹In, ⁹⁰Y,and ¹⁸⁶Re.

Conjugates of the antibody and cytotoxic agent are made using a varietyof bifunctional protein-coupling agents such asN-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane(IT), bifunctional derivatives of imidoesters (such as dimethyladipimidate HCI), active esters (such as disuccinimidyl suberate),aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis(p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such asbis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such astolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin canbe prepared as described in Vitetta et al., Science 238:1098 (1987).Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent forconjugation of radionucleotide to the antibody. See, WO94/11026.

In another embodiment, the antibody may be conjugated to a “receptor”(such as streptavidin) for utilization in tumor pretargeting wherein theantibody-receptor conjugate is administered to the patient, followed byremoval of unbound conjugate from the circulation using a clearing agentand then administration of a “ligand” (e.g., avidin) that is conjugatedto a cytotoxic agent (e.g., a radionucleotide).

Immunoliposomes The antibodies disclosed herein may also be formulatedas immunoliposomes. Liposomes containing the antibody are prepared bymethods known in the art, such as described in Epstein et al., Proc.Natl. Acad. Sci. USA 82:3688 (1985); Hwang et al., Proc. Natl. Acad.Sci. USA 77:4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545.Liposomes with enhanced circulation time are disclosed in U.S. Pat. No.5,013,556.

Particularly useful liposomes can be generated by the reverse-phaseevaporation method with a lipid composition comprisingphosphatidylcholine, cholesterol, and PEG-derivatizedphosphatidylethanolamine (PEG-PE). Liposomes are extruded throughfilters of defined pore size to yield liposomes with the desireddiameter. Fab′ fragments of the antibody of the present invention can beconjugated to the liposomes as described in Martin et al., J. Biol.Chem. 257:286-288 (1982) via a disulfide-interchange reaction. Achemotherapeutic agent (such as Doxorubicin) is optionally containedwithin the liposome. See, Gabizon et al., J. National Cancer Inst81(19):1484 (1989).

Pharmaceutical Compositions of Antibodies

Antibodies specifically binding an EGFL7 polypeptide identified herein,as well as other molecules identified by the screening assays disclosedhereinbefore, can be administered for the treatment of various disordersas noted above and below in the form of pharmaceutical compositions.

The formulation herein may also contain more than one active compound asnecessary for the particular indication being treated, preferably thosewith complementary activities that do not adversely affect each other.Alternatively, or in addition, the composition may comprise an agentthat enhances its function, such as, for example, a cytotoxic agent,cytokine, chemotherapeutic agent, or growth-inhibitory agent. Suchmolecules are suitably present in combination in amounts that areeffective for the purpose intended.

The active ingredients may also be entrapped in microcapsules prepared,for example, by coacervation techniques or by interfacialpolymerization, for example, hydroxymethylcellulose orgelatin-microcapsules and poly-(methylmethacylate) microcapsules,respectively, in colloidal drug delivery systems (for example,liposomes, albumin microspheres, microemulsions, nano-particles, andnanocapsules) or in macroemulsions. Such techniques are disclosed inRemington's Pharmaceutical Sciences, supra.

The formulations to be used for in vivo administration must be sterile.This is readily accomplished by filtration through sterile filtrationmembranes.

Sustained-release preparations may be prepared. Suitable examples ofsustained-release preparations include semipermeable matrices of solidhydrophobic polymers containing the antibody, which matrices are in theform of shaped articles, e.g., films, or microcapsules. Examples ofsustained-release matrices include polyesters, hydrogels (for example,poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides(U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradablelactic acid-glycolic acid copolymers such as the LUPRON DEPOT™(injectable microspheres composed of lactic acid-glycolic acid copolymerand leuprolide acetate), and poly-D-(−)-3-hydroxybutyric acid. Whilepolymers such as ethylene-vinyl acetate and lactic acid-glycolic acidenable release of molecules for over 100 days, certain hydrogels releaseproteins for shorter time periods. When encapsulated antibodies remainin the body for a long time, they may denature or aggregate as a resultof exposure to moisture at 37° C., resulting in a loss of biologicalactivity and possible changes in immunogenicity. Rational strategies canbe devised for stabilization depending on the mechanism involved. Forexample, if the aggregation mechanism is discovered to be intermolecularS—S bond formation through thio-disulfide interchange, stabilization maybe achieved by modifying sulfhydryl residues, lyophilizing from acidicsolutions, controlling moisture content, using appropriate additives,and developing specific polymer matrix compositions.

Methods of Treatment Using the Antibody

It is contemplated that the antibodies to an EGFL7 polypeptide may beused to treat various angiogenesis associated conditions as noted above.

The antibodies are administered to a mammal, preferably a human, inaccord with known methods, such as intravenous administration as a bolusor by continuous infusion over a period of time, by intramuscular,intraperitoneal, intracerobrospinal, subcutaneous, intra-articular,intrasynovial, intrathecal, oral, topical, or inhalation routes.Intravenous administration of the antibody is preferred.

Other therapeutic regimens may be combined with the administration ofthe antibodies of the instant invention as noted above. For example, ifthe antibodies are to treat cancer, the patient to be treated with suchantibodies may also receive radiation therapy. Alternatively, or inaddition, a chemotherapeutic agent may be administered to the patient.Preparation and dosing schedules for such chemotherapeutic agents may beused according to manufacturers' instructions or as determinedempirically by the skilled practitioner. Preparation and dosingschedules for such chemotherapy are also described in ChemotherapyService, Ed., M. C. Perry (Williams & Wilkins: Baltimore, Md., 1992).The chemotherapeutic agent may precede, or follow administration of theantibody, or may be given simultaneously therewith. The antibody may becombined with an anti-estrogen compound such as tamoxifen or EVISTA™ oran anti-progesterone such as onapristone (see, EP 616812) in dosagesknown for such molecules.

If the antibodies are used for treating cancer, it may be desirable alsoto administer antibodies against other tumor-associated antigens, suchas antibodies that bind to one or more of the ErbB2, EGFR, ErbB3, ErbB4,or VEGF receptor(s). These also include the agents set forth above.Also, the antibody is suitably administered serially or in combinationwith radiological treatments, whether involving irradiation oradministration of radioactive substances. Alternatively, or in addition,two or more antibodies binding the same or two or more differentantigens disclosed herein may be co-administered to the patient.Sometimes, it may be beneficial also to administer one or more cytokinesto the patient. In a preferred embodiment, the antibodies herein areco-administered with a growth-inhibitory agent. For example, thegrowth-inhibitory agent may be administered first, followed by anantibody of the present invention. However, simultaneous administrationor administration of the antibody of the present invention first is alsocontemplated. Suitable dosages for the growth-inhibitory agent are thosepresently used and may be lowered due to the combined action (synergy)of the growth-inhibitory agent and the antibody herein.

In one embodiment, vascularization of tumors is attacked in combinationtherapy. The anti-EGFL7 antibody and another antibody (e.g., anti-VEGF)are administered to tumor-bearing patients at therapeutically effectivedoses as determined, for example, by observing necrosis of the tumor orits metastatic foci, if any. Additional anti-tumor agents can be furtheradministered, such as alpha-, beta-, or gamma-interferon, anti-HER2antibody, heregulin, anti-heregulin antibody, D-factor,interleukin-1(IL-1), interleukin-2 (IL-2), granulocyte-macrophage colonystimulating factor (GM-CSF), or agents that promote microvascularcoagulation in tumors, such as anti-protein C antibody, anti-protein Santibody, or C4b binding protein (see, WO 91/01753, published 21 Feb.1991), or heat or radiation.

In other embodiments, a FGF or PDGF antagonist, such as an anti-FGF oran anti-PDGF neutralizing antibody, is administered to the patient inconjunction with the anti-EGFL7 antibody. Treatment with anti-EGFL7antibodies preferably may be suspended during periods of wound healingor desirable neovascularization.

For the prevention or treatment of cardiovascular, endothelial, andangiogenic disorder, the appropriate dosage of an antibody herein willdepend on the type of disorder to be treated, as defined above, theseverity and course of the disease, whether the antibody is administeredfor preventive or therapeutic purposes, previous therapy, the patient'sclinical history and response to the antibody, and the discretion of theattending physician. The antibody is suitably administered to thepatient at one time or over a series of treatments.

For example, depending on the type and severity of the disorder, about 1μg/kg to 50 mg/kg (e.g., 0.1-20 mg/kg) of antibody is an initialcandidate dosage for administration to the patient, whether, forexample, by one or more separate administrations, or by continuousinfusion. A typical daily or weekly dosage might range from about 1μg/kg to 100 mg/kg or more, depending on the factors mentioned above.For repeated administrations over several days or longer, depending onthe condition, the treatment is repeated or sustained until a desiredsuppression of disorder symptoms occurs. However, other dosage regimensmay be useful. The progress of this therapy is easily monitored byconventional techniques and assays, including, for example, radiographictumor imaging.

Articles of Manufacture with Antibodies

An article of manufacture containing a container with the antibody and alabel is also provided. Such articles are described above, wherein theactive agent is an anti-EGFL7 antibody.

Diagnosis and Prognosis of Tumors Using Antibodies

If the indication for which the antibodies are used is cancer, whilecell-surface proteins, such as growth receptors over expressed incertain tumors, are excellent targets for drug candidates or tumor(e.g., cancer) treatment, the same proteins along with EGFL7polypeptides find additional use in the diagnosis and prognosis oftumors. For example, antibodies directed against the EGFL7 polypeptidesmay be used as tumor diagnostics or prognostics.

For example, antibodies, including antibody fragments, can be usedqualitatively or quantitatively to detect the expression of genesincluding the gene encoding the EGFL7 polypeptide. The antibodypreferably is equipped with a detectable, e.g., fluorescent label, andbinding can be monitored by light microscopy, flow cytometry,fluorimetry, or other techniques known in the art. Such binding assaysare performed essentially as described above.

In situ detection of antibody binding to the marker gene products can beperformed, for example, by immunofluorescence or immunoelectronmicroscopy. For this purpose, a histological specimen is removed fromthe patient, and a labeled antibody is applied to it, preferably byoverlaying the antibody on a biological sample. This procedure alsoallows for determining the distribution of the marker gene product inthe tissue examined. It will be apparent to those skilled in the artthat a wide variety of histological methods are readily available for insitu detection.

The following Examples are offered for illustrative purposes only, andare not intended to limit the scope of the present invention in any way.

The disclosures of all patent and literature references cited in thepresent specification are hereby incorporated by reference in theirentirety.

EXAMPLES

Commercially available reagents referred to in the Examples were usedaccording to manufacturer's instructions unless otherwise indicated. Thesource of those cells identified in the following Examples, andthroughout the specification, by ATCC accession numbers is the AmericanType Culture Collection, Manassas, Va. 20108.

All references cited herein are hereby incorporated by reference.

Example 1 Cloning of EGFL7

EGFL7 was identified and cloned in an effort to discover novel humansecreted and transmembrane proteins, particularly those involved in theregulation of vascular development. Details of the cloning andexpression of human EGFL7 are described in, for example, patentapplication US20030224948A1 (wherein EGFL7 is identified as PRO1449).Briefly, whole mount in situ hybridization screens were performed toidentify secreted factors and receptors that are enriched in mouseembryonic vasculatures. By way of signal sequence prediction andextracellular domain homology searching, hundreds of human and mousecDNAs representing putative secreted factors and receptors wereidentified and collected. Using the mouse cDNAs as templates, riboprobeswere generated and in situ hybridizations were performed on whole mouseembryos ranging from E7.5 to E14.5. This developmental time window waschosen because it encompasses many key stages in vasculogenesis andangiogenesis. Among many genes identified from this screen, EGFL7 isuniquely expressed in the endothelia of actively growing blood vessels.See expression details below.

Xenopus EGFL7 was identified as a rough draft derived from a singlegenbank entry BC044267. Zebrafish EGFL7 was cloned by low stringency PCRand subsequent screening of a cDNA library made from 24hpf embryos,based on the homology among three known species (human, mouse andxenopus). The sequences of zebrafish EGFL7 cDNA, partial genomic DNA andamino acid are shown in FIG. 1B. EGFL8 was identified by BLAST usingEGFL7 sequences.

Radiation hybrid mapping experiments using the T51 panel placed thezebrafish EGFL7 in linkage group 21 (LG21), close to the EST markerfk20d12.yl (Accession number AW566846). This region of zebrafish LG21appears to be syntenic with human chromosome 9q33 to 9q34, the locuswhere human EGFL7 resides. The following genes are found within thishuman locus: Notchl (9q34), carboxyl ester lipase (CELL; 9q34), andproteasome subunit beta 7 (psmb7; 9q33). These genes are present in theregion of LG21 where zebrafish EGFL7 mapped (LG21, 19.6-29.0 CM).

The EGFL7 gene encodes a putative secreted protein with a relativemolecular mass of ˜30kD. EGFL is evolutionary conserved. See FIG. 1 a.The human (Homo sapiens) amino acid sequence shares 77.45%, 47.12% and42.96% homology to that of the mouse (Mus musculus), xenopus (Xenopuslaevis) and zebrafish (Danio rerio), respectively.

The EGFL7 protein contains a signal sequence, an EMI domain at theN-terminus (EMI domain is present in a number of extracellular matrixassociated proteins involved in regulating cell adhesion), followed bytwo EGF-like domains and a leucine and valine rich C-terminal region.The mammalian EGFL7 belongs to a small gene family. BLAST searchesidentified one closely related gene EGFL8, which has an identical domainorganization as EGFL7. Interestingly, this gene family appears to bemore complex in mammals, since no EGFL8 orthologue has been identifiedin several fish genomes (Danio rerio, Medaka and Fugu).

The cDNA encoding human EGFL7 was deposited under the terms of theBudapest Treaty with the American Type Culture Collection, 10801University Blvd., Manassas, Va. 20110-2209, USA (ATCC), with ATCCDeposit No. 203243 (deposited on Sep. 9, 1998).

These deposits were made under the provisions of the Budapest Treaty onthe International Recognition of the Deposit of Microorganisms for thePurpose of Patent Procedure and the Regulations thereunder (BudapestTreaty). This assures maintenance of a viable culture of the deposit for30 years from the date of deposit. The deposits will be made availableby ATCC under the terms of the Budapest Treaty, and subject to anagreement between the assignee of the present application and ATCC,which assures permanent and unrestricted availability of the progeny ofthe culture of the deposit to the public upon issuance of the pertinentU.S. patent or upon laying open to the public of any U.S. or foreignpatent application, whichever comes first, and assures availability ofthe progeny to one determined by the U.S. Commissioner of Patents andTrademarks to be entitled thereto according to 35 USC § 122 and theCommissioner's rules pursuant thereto (including 37 CFR § 1.14 withparticular reference to 886 OG 638).

The assignee of the present application has agreed that if a culture ofthe materials on deposit should die or be lost or destroyed whencultivated under suitable conditions, the materials will be promptlyreplaced on notification with another of the same. Availability of thedeposited material is not to be construed as a license to practice theinvention in contravention of the rights granted under the authority ofany government in accordance with its patent laws.

Example 2 Expression of EGFL7

To elucidate the expression pattern of EGFL7, whole mount in situhybridization, immunofluorescent staining and radioactive in situhybridization were carried out on mouse and zebrafish embryos as well asmouse and human tissue sections.

Zebrafish and Mouse Strains

Mouse embryos were harvested from timed-pregnant CD-1 mice. Tüebingenlong fin (TL) wild-type zebrafish line, ˜30 hpf cloche (Clo^(m39))homozygous mutant embryos and their wild-type siblings were used in theexpression and activity studies described herein below. Adult zebrafishand embryos were maintained as previously described (Westerfield 1993Zebrafish Book).

Radioactive in situ Hybridization

Tissues were processed for in situ hybridization by a method describedpreviously. Phillips et al. (1990) Science 250:290-4. ³³P-UTP-labelledRNA probes were generated as described. Melton et al. (1984) NucleicAcids Research 12:7035-56. EGFL7 sense and antisense probes weresynthesized from two human cDNAs and one murine cDNA that correspond tonucleotides 382 to 1062, -137 to 150, and 173 to 774, respectively.(Nucleotide A in the initiation codon is counted as nucleotide #1).

Wholemount in situ Hybridizations

Wholemount in situ hybridizations were carried out as described withslight modifications. Shimamura et al. Development 120:2225-2234 (1994).Stained embryos were cleared in a 2:1 mixture of benzyl alcohol/benzylbenzoate for photography. Sense and antisense riboprobes were made usingthe following templates: a murine EGFL7 partial cDNA clone (IMAGE clone519249, Genbank accession: AA107358); a zebrafish EGFL7 partial cDNAclone corresponding to nucleotides 169 to 807; all other molecularmarkers were from the Fishman (MGH), Stainier (UCSF) and Weinstein (NIH)labs. Following whole-mount in situ hybridization analysis, embryos werere-fixed in 4% paraformaldehyde (PFA) in 1×PBS, dehydrated through anethanol series, and embedded in JB-4Plus plastic (Polysciences). 5 μmsections were counterstained with 0.2% nuclear fast red, and mounted inCytomount 60.

AP Staining

Endogenous alkaline phosphatase activity in 48 hpf whole-mount zebrafishembryos was detected as described previously. Childs et al. Development129:973-982 (2002).

Deconvolution Microscopy

Embryos were fixed overnight at 4° C. in 4% PFA, cryoprotected in 20%sucrose/PBS, snap frozen in 7.5% gelatin/15% sucrose and sectioned.Slides were air dried, permeabilized in 1×PBS/0.1% Triton X-100/1%DMSO,blocked for 20 min in the above solution plus 1% BSA, stained with 66 nMALEXA Fluor594-phalloidin (Molecular Probes) for 20 min, washed, mountedwith Vectashield DAPI (Vector labs.) and analyzed using a DeltavisionDeconvolution Microscope with 60× oil objective.

Immunofluorescent Staining

Armenian hamsters were immunized with recombinant murine EGFL7 proteinexpressed in E. coli. Monoclonal antibodies were generated by hybridomafusion and subcloning. Two monoclonal antibodies 1C8 and 5H7 thatrecognize different epitopes were used for immunofluorescent staining.Mouse tissues were snap frozen and cryosectioned. Fixed cells or 5 μmunfixed tissue sections were stained as described. Parker et al. Methodsin Cell Biology 59:313-36 (1999). Antibodies used in this study are:Anti-ZO-1 mab (Zymed Inc. Cat. # 33-9100); anti-GFP (Torrey PinesBiolabs, Cat. # TP401); anti-vinculin mab (Sigma).

Results

The expression pattern of EGFL7 is also evolutionary conservedisconserved across species. In mouse, human and zebrafish embryos, highlevels of EGFL7 transcripts were detected in endothelial progenitors andECs in all vessels (FIGS. 2 a, 2 b, 2 g, 2 j-2 m), as well as theendocardium. Strong vascular expression persisted throughout embryonicand neonatal development; however, the message was undetectable in manyadult organs (FIG. 2 h). In adult mice, a few highly vascularized organssuch as the lung, heart and kidney continued to express EGFL7 in a smallsubset of vessels. Interestingly, EGFL7 expression was strongly upregulated in many proliferative tissues including tumors (FIG. 2 i),reproductive organs during pregnancy (FIG. 2 c), and inflamed tissues.Moreover, strong EGFL7 expressions were found in primary human diseasetissues including, but not limited to, lung adenocarcinoma and sqamouscell carcinoma, renal cell carcinoma, prostate carcinoma, ovariancarcinoma, hepatic carcinoma, gastric carcinoma, chondrosarcoma,osterosarcoma, neovascular membranes from diseased eyes and sites ofinflammation.

This unique expression pattern suggests that high levels of EGFL7 areassociated with vascular growth and remodeling. EGFL7 was not detectedoutside of the cardiovascular and hematopoietic systems, thisobservation was confirmed by the fact that EGFL7 expression iscompletely abolished in the avascular zebrafish mutant cloche (FIG. 2n). Stainier et al. Dev. Suppl. 121:3141-3150 (1995).

Immunofluorescence staining shows that the EGFL7 protein is secreted butremains in the vicinity of the ECs (inset of FIG. 2 c), apparentlyassociated with the extracellular matrix. Further study using a tumormodel treated with an anti-VEGF antibody showed that after tumorvasculature became fragmented due to the anti-VEGF treatment, EGFL7remained in the ECM tracks of the regressed tumor vessels. This maysuggest a potentially important role of EGFL7 in supporting tumorvessels to eventually grow back and thus “escape” the anti-VEGFtreatment.

Example 3 Phenotypic Analysis of Animals with Reduced EGFL7 Activity

A. Vascular Defects in the EGFL7 Knockdown Zebrafish

In a recent report, conditioned medium containing the recombinant EGFL7protein is shown to inhibit smooth muscle cell (SMC) migration in vitro.Soncin et al. EMBO J. 22:5700-5711 (2003). However, its in vivo functionhas not been defined. To uncover the in vivo biological function ofEGFL7, the model organism zebrafish was used because of the availabilityof tools to study vasculogenesis and angiogenesis, and the ease tomanipulate gene expression in embryos. Fishman et al. CirculationResearch 74:757-63 (1994); Weinstein et al. Cardiovascular Research 31:E17-24 (1996); Dooley et al. Current Opinion in Genetics & Development10:252-6(2000); Nasevicius & Ekker Nature Genetics 26:216-20 (2000).Furthermore, it was found that Egfl8 was expressed in a subset of bloodvessels and peripheral nerves in mouse embryos, making it a potentialredundant factor for EGFL7. On the other hand, no Egfl8 orthologue hasbeen found in zebrafish and several other fish genomes. Therefore,zebrafish provides a unique tool for defining the biological function ofthis gene family.

Gene knockdown experiments were performed using two different morpholinoantisense oligos targeting the zebrafish EGFL7: that ensures stabilityand specificity in vivo, and they function by specifically inhibitingthe translation or splicing of targeted genes. oligo AS_(-Z(-47))hybridizes to the 5′ UTR and blocks translation; oligo AS₁₉₅ hybridizeswith an exon-intron junction, resulting in intron retention and hencepremature translation termination. Positions of the two antisense oligosare indicated in FIG. 1B. Randomized controls are CON(-47):ACGACGGTCACGATGAATGGAGAGT; and CON(195): CATTGTTCATCGTCTTGTTGCGTGT.

A fluorescein tag was added to aid in identifying embyros that wereproperly injected and to confirm uniform distribution of theoligonucleotides in developing embryos. 5 mM oligo stock solution (˜40mg/ml) in water was diluted in 1× Danieu's solution (58 mM NaCl, 0.7 mMKCl, 0.4 mM MgSO4, 5 mM HEPES, pH 7.6) with 0.25% phenol red. A bolus ofapproximately 4.6 nl was injected into each 1-cell to 8-cell stageembryo using a Drummond Nanoject microinjector. Titration experimentsrevealed that injection of 4 ng antisense oligo per embryo causedspecific vascular defects with no observable defects in otherstructures, along with no significant increase in mortality in therandomized control oligo-injected embryos.

Both oligos gave identical phonotypical results. When examined after theonset of circulation [˜24 hours post fertilization (hpf)], more than 40%of the EGFL7 knockdown embryos (KDs) showed overt signs of vasculardefects: they either have no circulation at all, or develop anincomplete circulatory loop; many have pericardial edema and hemorrhage(FIG. 3 a). In contrast, only 3% of the control oligo injected fish haveminor vascular defects.

Furthermore, expression patterns of the followingseveral vascularendothelial markers were analyzed, including: flil¹⁴, flkl¹⁵, and tiel ,ephrinB2 and gridlock (arterial EC marker), flt4 and EphB4 (venous ECmarker), and endogenous alkaline phosphatase activity. Brown et al.Mech. Dev. 90:237-252 (2000); Fouquet et al. Dev. Biol. 183:37-48(1997); Liao et al. Development 124:381-389 (1997); Lyons et al. Dev.Dyn. 212:133-140 (1998); Lawson & Weinstein Nature Rev. Genet 3:674-682(2002); Zhong et al. Science 287:1820-1824 (2000); Childs et al.Development 129:973-982 (2002). Knockdown experiments were also carriedout in a flkl-promoter-GFP transgenic line. ¹⁶From the 7-somite stage to30 hpf, the overall spatial distribution and intensity of the abovemarkers were unaffected in the KDs, furthermore, all primary arteriesand veins were formed in the correct locations in the KDs (FIGS. 3, 4),indicating that there is no significant defect in early ECdifferentiation, proliferation and migration. at 30 hpf (hours postfertilization). However, tubulogenesis throughout the entire system wasdisrupted in the KDs. At 30 hpf, many primary vessels in the theZ(-47)KDs had either disorganized lumens or no lumen at all (FIG. 3 c-d,3 h). The partially formed Se detected at 30 hpf appear to be unstable,since endogenous AP staining, which detects polarized endothelium at 48hpf, show no Se in all the Z(-47) injected fish, while Se in the controloligo injected fish were unaffected (FIG. 4 d and 4 e). Furthermore, inthe transverse sections of the AP stained fish, no structure resemblingSe can be seen in the Z(-47) injected fish (FIG. 4 f), suggesting thatthe partial Se seen at 30 hpf may have regressed as development proceed.The prevalence of the tubulogenesis defect displayed by molecularmarkers is between 75 and 85% in multiple experiments (FIG. 3 d). Forinstance, flil staining at 30 hpf revealed that 76% (28/37) of theZ(-47)KDs had vasculature that was severely malformed tubulogenesisdefect, whereas all control embryos (n=37) developed normal vasculartubes. To confirm the knockdown specificity, the vascular phenotypecaused by AS₋₄₇ was rescued by the EGFL7 coding RNA without the 5′untranslated region.

Lack of lumen formation in the EGFL7 KDs was verified by the findingthat major vessels in these embryos could not be filled with dye.Although it is possible that the tubulogenesis defect is a consequenceof vascular collapse due to lack of blood flow, the followingobservations make it unlikely: first, cardiac contractile function wasnormal in the EGFL7 KDs; second, primary vessel lumen formation andshort term maintenance were normal in the silent heart mutants that lackcirculation. Sehnert et al. Nature Genet. 31:106-110 (2002); Isogai etal. Development 130:5281-5290 (2003).

The EGFL7 KD animals also showed progressive angiogenesis defects. Theinitial sprouting of intersegmental vessels (ISVs) occurred normally inthe mutants at 22-24 hpf (FIG. 3 b). However, these secondary vesselsgradually disappeared, as the ISVs were partially missing at 30 hpf(FIG. 2 c-d), and were completely eliminated by 48-72 hpf. It is likelythat lack of circulation partly contributes to the angiogenesis defect,since it is documented that ISVs undergo regression in the absence ofblood flow. Isogai et al. Development 130:5281-5290 (2003). Due to thedominant phenotype in the primary vessels, the exact role of EGFL7 inangiogenesis can be further defined using methods such as inducibleknockout.

Because vascular development is dependent on neighboring tissues,question remains as to whether the vascular defect seen in the EGFL7 KDsis an indirect consequence of disrupting surrounding tissues. Brown etal. Mech. Dev. 90:237-252 (2000); Sumoy et al. Mech. Dev. 63:15-27(1997); Vokes & Krieg Dev. Suppl. 129:775-785 (2002). In cross sectionsof the KDs, a normal complement of tissues appear to exist (FIG. 3).Furthermore, in situ hybridization with fkd7, ntl, axial /fkdl and gatalillustrated that all axial structures and the hematopoietic lineagedeveloped normally in the KDs. Odenthal & Nusslein-Volhard Dev. GenesEvol. 208:245-258 (1998); Schulte-Merker et al. Development116:1021-1032 (1992); Strahle et al. Genes Dev. 7:1436-1446 (1993);Parker et al. Methods Cell Biol. 59:313-336 (1999). After the onset ofcirculation, gatal⁺ cells in the KDs remained in the posteriorventrolateral region of the embryo where they initially developed,confirming that the vasculature is defective. Finally, defectiverecruitment of SMC is an unlikely causative factor since there was noevidence of perivascular SM22A expression in wild type embryos at the26-somite stage, a time point when the vascular defects were obvious inthe KDs. Taken together, the data suggests that failure of vasculartubulogenesis is a primary defect caused by EGFL7 knockdown.

Since EC number dictates vascular morphogenesis, further observationfocused on whether EC number was altered in the EGFL7 KDs. Fong et al.Development 126:3015-3025 (1999). Serial cross sections showed thatknocking down EGFL7did not change the total number of ECs at all axiallevels regardless of developmental stage (FIG. 4). Furthermore, based onephrinB2 and flt4 expression, and the differential regulation of flklpromoter between artery and vein in the flkl:GFP embryos, arterial andvenous EC numbers were also found to be unaffected (FIG. 4). In contrastto EGFL7, knocking down vegf a known mitogenic factor for EC, reduced ECnumber significantly, and subsequently disrupted tube formation. Thus,the data indicates that EGFL7 plays a unique role that is distinctivefrom VEGF and is mainly required during vascular tubulogenesis.

In order to describe the vascular phenotype at a cellular level, a timecourse analysis was carried out using the flkl:GFP fish. Serial crosssections of the trunk and longitudinal sections of the head were takenat the 22-, 24-, 26-somite (before circulation), 24 hpf (onset ofcirculation), and 30 hpf stages. Analyses of these sections reveal aseries of cellular events during the cord-to-tube transition in thecontrol embryos. At the 22-somite stage, arterial and venous angioblastscoalesced into single cords. Extensive tight junctions revealed intimateconnections among angioblasts. Around the 24-somite stage, gradualseparation of angioblasts was evident by substantial refinement of tightjunctions. By the 26-somite stage, angioblasts were sufficientlysegregated, such that arterial and venous angioblasts occupied distinctdomains and aligned in the form of rudimentary tubes. Subsequently, ECsunderwent extensive morphological changes and became squamous, therebyrendering the vascular tubes their final shape. This sequence of eventsleading to the formation of major vascular tubes was severely impairedin the EGFL7 KDs. At all the stages examined, the knockdown angioblastsfailed to separate and retain extensive tight junctions. They alsofailed to change shape at the later stages (FIG. 4 h).

B. Reduced Tumor Growth and Defective Vasculature in the EGFL7 KnockoutMice

To further elucidate EGFL7's function in mammalian animals, mEGFL7knockout (KO) mice were generated and used as host animals for tumorimplants. The KO mice were originally generated in a 129/BL6 background,and have been backcrossed to BL6. Animals used in the experiment were 3to 4 generation backcrossed.

Over 500,000 B16(F10) melanoma tumor cells were injected subcutaneouslyin the dorsal flank of each animal. Injection sites were examined dailyfor tumor incidence. Tumors were measured regularly to determine growthrate. The tumor growth rate of EGFL7^(−/−) homozygous animals werecompared with that of EGFL7^(+/−) heterozygous or wildtype littermates.

As shown in FIGS. 6 and 7, B16 melanoma tumor growth was significantlyreduced in animals with complete knockout of EGFL7.

A similar tumor growth study using Lewis lung carcinoma (LLC) tumorimplants also showed reduced tumor growth in homozygous EGFL7^(−/−) KOmice. Furthermore, LLC tumors in a subset of EGFL7^(−/−) KO mice failedto vascularize, implicating EGFL7's role in tumor vasculargenesis.

A study comparing retinal vasculature formation in the EGFL7^(−/−) KOmice versus the wild type mice showed that lack of EGFL7 functionresulted in delayed retinal vascular migration, despite the relativenormal retinal formation. Moreover, in the wild type mice, EGFL7expression was localized to the migration front of retinal development.

Example 4 EGFL7 Supports EC Adhesion and Migration

Failure of EC separation as shown in Example 3 indicates that either ECmotility or adhesion is improperly regulated in the EGFL7 KDs. In vitroendothelial cell migration and adhesion assays were carried out todistinguish between these two possibilities.

Plates were coated with 5 μg/cm² protein [BSA (Sigma), collagen(Upstate), Fibronectin (Sigma), recombinant human EGFL7 produced in E.coli at Genentech]. After PBS rinses, HUVEC (Cambrex) were plated at adensity of 5×10⁵/cm² in EGM2 medium (Cambrex) and centrifuged for 5 minat 140×g to synchronize cell attachment, and then incubated. To analyzespecificity, plates were pre-incubated with the indicated concentrationsof antibody prior to HUVEC plating.

Monoclonal anti-human EGFL7 antibodies were generated using therecombinant human and mouse EGFL7 polypeptides as immunogen.Antibody-antigen bindings were evaluated by ELISA. The blockingactivities of these antibodies were tested in assays such as the HUVECadhesion assay. Intial assays identified anti-EGFL7 Mabs from hybridoma10G9, 18F7, 3A5 and 1B12 as having the strongest inhibitory activity.

To determine adhesion strength, inverted plates were centrifuged at 46,183 or 411×g after 60 min of incubation. The number of adherent cellswas quantified using a fluorescence-based assay (CyQUANT, Molecularprobes) and readouts were taken using a fluorescence plate reader.(Spectramax, Molecular Devices).

The results showed that EGFL7 coated on culture plates enhanced HUVECadhesion (FIG. 5). Interestingly, the strength of adhesion promoted byEGFL7 was significantly weaker than other classic cell adhesionmolecules such as fibronectin and collagens (FIG. 5 e). Moreover, thekinetics of HUVEC adhesion to EGFL7 was much slower than othersubstrates (FIG. 5 g). Taking into account the EGFL7 expression pattern,subcellular localization, in vivo function, and cell adhesionproperties, it is suggested that during active vascular growth, EGFL7may provide a permissive substrate that favors motility over stableattachment, thereby enabling the local movement of angioblasts that isrequired for tube formation. Furthermore, migration assays using EGFL7coated substrates with or without blocking anti-EGFL7 Mabs showed thatEGFL7 substrate support HUVEC migration.

An in vitro tube formation assay in the presence of selected anti-EGFL7Mabs showed that some of the blocking antibodies, including those fromhybridoma 1 8F7, 3A5, 10G9 and 1B 12, significantly altered in vitrotube formation, further supporting the critical role of EGFL7 duringvascular formation.

The foregoing written specification is considered to be sufficient toenable one skilled in the art to practice the invention. However,various modifications of the invention in addition to those shown anddescribed herein will be apparent to those skilled in the art from theforegoing description and fall within the scope of the appended claims.

1. A method of reducing or inhibiting angiogenesis in a subject having apathological condition associated with angiogenesis, comprisingadministering to the subject an EGFL7 antagonist capable of interferingwith EGFL7-induced endothelial cell migration, thereby reducing orinhibiting angiogenesis in the subject.
 2. The method of claim 1,wherein the EGFL7 antagonist is an anti-EGFL7 antibody.
 3. The method ofclaim 1, wherein the pathological condition is a neoplasm.
 4. The methodof claim 3, wherein the neoplasm is a carcinoma.
 5. The method of claim1, wherein the pathological condition is associated with the eye.
 6. Themethod of claim 5, wherein the pathological condition is an intraocularneovascular disease.
 7. The method of claim 1, further comprisingadministering to the subject an anti-angiogenic agent.
 8. The method ofclaim 7, wherein the anti-angiogenic agent is administered prior to orsubsequent to the administration of the EGFL7 antagonist.
 9. The methodof claim 7, wherein the anti-angiogenic agent is administeredconcurrently with the EGFL7 antagonist.
 10. The method of claim 7,wherein the anti-angiogenic agent is an antagonist of vascularendothelial cell growth factor (VEGF).
 11. The method of claim 10,wherein the VEGF antagonist is an anti-VEGF antibody.
 12. The method ofclaim 11, wherein the anti-VEGF antibody is bevacizumab.
 13. The methodof claim 1, wherein the EGFL7 antagonist's ability to interfere withEGFL7-induced endothelial cell migration is detected in an in vitro cellmigration assay.
 14. A method of enhancing efficacy of ananti-angiogenic agent in a subject having a pathological conditionassociated with angiogenesis, comprising administering to the subject anEGFL7 antagonist in combination with the anti-angiogenic agent capableof inhibiting angiogenesis, thereby enhancing said anti-angiogenicagent's inhibitory activity.
 15. The method of claim 14, wherein theEGFL7 antagonist is an anti-EGFL7 antibody.
 16. The method of claim 14,wherein the pathological condition is a neoplasm.
 17. The method ofclaim 16, wherein the neoplasm is a carcinoma.
 18. The method of claim14, wherein the pathological condition is associated with the eye. 19.The method of claim 18, wherein the pathological condition is anintraocular neovascular disease.
 20. The method of claim 17, furthercomprising administering a chemotherapeutic agent.